SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions October categorized by USPTO classification 10/06

20060239907 - Stealthy nano agents: Stealthy nanoagents are provided comprising inorganic shells containing pluralities of nanoagents. The nanoagents are isolated from the environment of the shells. Thereapeutics, imaging and diagnostic methods are also provided....

20060239908 - Compositions for inhalation: The present invention relates to new pharmaceutical compositions for inhalation containing one or more, preferably one anticholinergic 1 in combination with one or more betamimetics 2 and one or more steroids 3, processes for preparing them and their use in the treatment of respiratory complaints....

20060239911 - Antibodies with immune effector activity and that internalize in endosialin-positive cells: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic...

20060239910 - Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific...

20060239912 - Carrier molecules: The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. More particularly, the present invention provides deimmunized immunointeractive molecules and even...

20060239909 - Treatment of protein degradation disorders: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to...

20060239914 - Gastrin releasing peptide compounds: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the...

20060239913 - Peptide conjugate for magnetic resonance imaging: The invention relates to new compounds and compositions for the imaging diagnostic of pathologies, namely for cardiovascular diseases, more precisely atherosclerosis disease. These compounds are contrast agents useful namely in the field of magnetic resonance imaging MRI and nuclear medicine. The compounds comprise a particular peptidic MMP inhibitor coupled with...

20060239920 - Imaging methods for early detection of brain tumors following embryonic stem cell implants: Non-invasive imaging methods and minimally invasive sensing methods are used for assessing the viability of cells implanted in the central nervous system for therapeutic purposes and for detecting the transformation of such cells, including embryonic stem cells, into brain tumors. In particular, the present invention provides an imaging means for...

20060239915 - Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases: The present invention is in the field of diagnostic imaging. In one aspect, the invention relates to novel imaging agents comprising synthetic macrophage scavenger receptor A antagonists, said imaging agents being useful in the diagnostic imaging of cardiovascular disease. Also claimed in the present invention is a pharmaceutical composition comprising...

20060239917 - Method for forecasting the contrast medium flow in a living body: e

20060239918 - Method for forecasting the contrast medium flow in a living body:

20060239919 - Mr coronary angiography with a fluorinated nanoparticle contrast agent at 1.5 t: Disclosed herein is a medical imaging technique that uses a fluorinated nanoparticle contrast agent for imaging of an interior portion of a body. The fluorinated nanoparticles preferably comprise nontargeted intravascular fluorocarbon or perfluorocarbon nanoparticles. The interior body portion may be a patient's vasculature, and the medical imaging is preferably noninvasive...

20060239916 - Use of cyanine dyes for the diagnosis of proliferative diseases: The present invention concerns the use of the cyanine dye SF64 for the diagnosis of proliferative diseases upon administration of less than 5 mg/kg body weight....

20060239924 - Compositions for delivery of therapeutics and other materials, and methods of making and using the same: In part, the present invention is directed to biocompatible compositions comprising a carrier with a first metal binding domain, a metal ion, an active agent with second metal binding domain and optionally a protective chain covalently attached to the polymeric carrier....

20060239923 - Gastrin releasing peptide compounds: New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging...

20060239926 - Specific high-relaxivity compounds: The invention relates to novel compounds that are useful for the diagnosis of many pathologies, in particular cardiovascular, cancer-related and inflammatory pathologies, and to pharmaceutical compositions comprising said compounds. These compounds comprise a component for targeting a pathological region, linked to a detection component which is effective in diagnostic terms....

20060239925 - Method of manufacturing pharmaceutical preparation containing liposomes: A method of manufacturing a liposome-containing preparation is disclosed, comprising (a) mixing one or more constituents of a liposome membrane, an aqueous solution of a water-soluble chemical and supercritical carbon dioxide at a temperature of 32 to 65° C. in a pressure vessel, and (b) evacuate the carbon dioxide to...

20060239921 - Real time vascular imaging during solid organ transplant: The invention provides methods and systems for imaging vessels in a subject. In certain embodiments the vessels may be associated with a solid organ transplant....

20060239922 - Water-soluble fluoro-substituted cyanine dyes as reactive fluorescence labelling reagents: in which at least one of groups R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 R11, R12, R13 and R14 is -L-M or -L-P, where L is a linking group, M is a target bonding group and P is a conjugated component, and at least one of groups...

20060239927 - Drug for airway administration: An agent for intra-airway administration comprising a compound having a PDE-IV inhibitory activity or the pharmaceutically acceptable salt thereof as an active ingredient which shows its concentration in lung tissues 350-times or more higher than its concentration in plasma when administered into the airway is provided. An agent for intra-airway...

20060239930 - Process for nebulizing aqueous compositions containing highly concentrated insulin: A process for nebulizing highly concentrated solutions of insulin for administration by inhalation....

20060239928 - Transmucosal administration of drug compositions for treating and preventing disorders in animals: The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable...

20060239929 - Use of a clobetasol spray formulation to treat psoriasis: The present invention provides a method for treating psoriasis, by spraying onto the skin with psoriasis daily for at least 4 weeks a pharmaceutical composition containing an effective amount of clobetasol propionate. A preferred pharmaceutical composition containing clobetasol propionate, ethyl alcohol, isopropyl myristate, and anionic surfactant....

20060239935 - Compositions for inhalation: e

20060239936 - Delivery of anti-migraine compounds through an inhalation route: The present invention relates to the delivery of anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing lidocaine, verapamil, diltiazem, isometheptene, or lisuride that are used in inhalation therapy. In a method aspect of the present invention, lidocaine, verapamil, diltiazem, isometheptene, or lisuride is administered to a...

20060239933 - Medical product: A medical product is disclosed. The medical product contains an accurately metered dose of at least one GLP medicament intended for pulmonary inhalation put into a moisture-tight, high barrier seal container. The medical product optionally also contains a dose of insulin. The container is adapted for application into a dry...

20060239931 - Pharmaceutical aerosol composition: An aerosol formulation comprising a biodegradable microsphere comprising a non-living reagent, such as a sub-unit vaccine, that produces a protective immune response in a mammal to whom it is administered. Nebulizers and inhalers containing such formulations are also described and claimed....

20060239932 - Pharmaceutical formulations comprising magnesium stearate: The invention relates to the use of magnesium stearate to inhibit or reduce chemical interaction between an active ingredient substance and a carrier in a solid pharmaceutical formulation, wherein the active ingredient substance is susceptible to chemical interaction with the carrier. An inhalable solid pharmaceutical formulation comprising (a) an active...

20060239934 - Superior control of blood glucose in diabetes treatment: Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration....

20060239937 - Stable foam cream: t

20060239938 - Dental balm and method of prevention of damage to teeth: A dental balm composition prevents damage to teeth which are prone to prolonged exposure to air or other drying conditions and which are therefore susceptible to tooth decay. The dental balm composition is comprised of an active decay preventing agent such as fluoride ion dispersed in a water insoluble adhesive...

20060239939 - Deodorant composition: It is intended to provide deodorant compositions which are nondetrimental to the environment and yet exhibit an excellent deodorizing effect on a wide range of offensive odor components including lower fatty acids. It is also intended to provide deodorant compositions giving off little or no foul odor derived from the...

20060239940 - Substance containing a polycation and a calcium salt: The invention relates to a substance containing a polycation and a calcium salt, and to a composition containing the substance. The substance and compositions containing the same exhibit adsorbability of a fungus body and adsorbability of a nucleic acid. The invention further includes an agent for adsorptive removal of a...

20060239943 - Formula and method for providing protection from dermatitis, sunlight and/or insects: A formula and a method for providing protection of skin of a user from dermatitis, sunlight and/or an insect. The formula is applied to an area of the skin of the user prior to exposing the area to the dermatitis, the sunlight and/or the insect. The formula has one or...

20060239941 - Metal oxide formulations: A composition is described which comprises an ingredient which is adversely affected by the presence of TiO2 and/or ZnO, and TiO2 and/or ZnO which has been doped with another element and/or reduced ZnO....

20060239942 - Stable transfer-resistant self-tanning gel containing a water-soluble or water-dispersible gelling agent: A self-tanning aqueous gel composition containing: (a) a cosmetically acceptable support; (b) at least one monocarbonyl or polycarbonyl self-tanning agent; (c) at least one aqueous phase gelling agent comprising at least one water-soluble or water-dispersible, crosslinked or non-crosslinked polymer or copolymer; d) at least one tinting agent; and (e) optionally,...

20060239944 - Sulfacetamide formulations for treatment of skin dermatoses: A topical composition for the treatment of mammalian skin dermatoses comprising a sulfacetamide or a derivative thereof and at least 1 sunscreen wherein the sunscreen is present in a sufficient amount to produce a sun protection factor of about 1.6 to about 20.6. Also provided is a method of treating...

20060239945 - Cleansing composition: A skin-lightening cleansing composition with a pH below 7.5 comprising 3% to 50% by weight of detergent active wherein nonionic detergent active when present, has a HLB in the range 5-18; and 0.01% to 20% by weight alkyl or cyclo alkyl resorcinol....

20060239946 - Cosmetic composition and method for treating keratinous materials, comprising a photodimerizable compound: The invention concerns generally a cosmetic composition comprising at least one cosmetic active principle and at least one photodimerizable compound enabling a material deposit to be provided on the keratinous materials, which is resistant to washing, and whereof the location is precisely controlled, capable of providing long-lasting cosmetic properties to...

20060239947 - Biliquid foams stable dispersions thereof and a corresponding process of manufacturing: A biliquid foam comprising from 10% to 98% by weight of a non-polar liquid other than a fuel and from 2 to 88% by weight of a continuous phase polar liquid comprising a C1-C4 alcohol, a liquid polyethylene glycol, ethylene glycol or propylene glycol, or mixtures thereof, in an amount...

20060239950 - Cosmetic compositions containing an aqueous dispersion of silicone elastomers and methods of use: The present invention provides an anti-aging composition comprising more than 30% by weight of an aqueous dispersion of silicone elastomer and an emollient system and methods of use thereof for improving skin condition....

20060239949 - Silicone elastomer exfoliating compositions: Compositions of the present invention comprise from about 40-99% of an aqueous suspension of silicone elastomer powder in a cosmetically acceptable vehicle. The compositions are useful as skin exfoliants when mechanical agitation is supplied, for example by rubbing with a hand. After exfoliation, little or no film or residue remains...

20060239952 - Cleaning composition and method for preparing the same: Cleaning compositions comprising (A) N-long-chain acyl neutral amino acid or a salt thereof, (B) N-long-chain acyl neutral amino acid dipeptide or a salt thereof, and (C) N-long-chain acyl neutral amino acid tripeptide or a salt thereof provide abundant foam, are excellent in foam retaining properties, and furnish a cleaned and...

20060239951 - Methods for stimulating hair growth by administering bmps: Methods and compositions for stimulating hair growth and inhibiting immune system activity by administering BMPs are provided. The methods and compositions can be used for treating or preventing disorders resulting in loss of hair, as well as a wide range of autoimmune disorders....

20060239953 - Rinse-off personal care compositions containing high modulus lipids: A rinsable personal care composition comprises (a) 0 to 75 weight percent of a surfactant; (b) 0.01 to 99 weight percent of a skin benefit agent comprising a high modulus lipid and an ester; and (c) 0 to 99 weight percent water....

20060239954 - Antimicrobial spray for use on pets: An antimicrobial liquid product is aqueous and/or alcoholic based for application to the feet of domesticated animals, particularly, the soles of the feet of domesticated animals, for the purpose of disinfecting or sanitizing the animal prior to the animal entering an area where pathogens are undesired. Examples of these areas...

20060239955 - Cosmetic composition: A cosmetic composition is provided which is substantially free of fatty acids and soap and yet displays the typical sensory and optical features of a vanishing cream. The composition comprises C12-C22 fatty alcohol, emulsifier, inorganic agent, polymer and water. The inorganic agent comprises smectite clay. The composition is mild and...

20060239948 - Alkyl silicone polyester resins: The present invention relates to a series of novel silicone polyesters which are prepared by crosslinking an alkyl dimethicone copolyol with a dimer acid. The reaction of the alkyl dimethicone copolyol and dimer acid results in a polyester having affinity to oils and that is highly lubricious on hair, skin...

20060239957 - Cosmetic and dermopharmaceutical compositions for skin prone to acne: The invention relates to the use of an extract of olive leaves (Olea europaea) which is titrated in oleanolic acid and which may or may not be associated with a Larrea divaricata extract which is titrated in nordihydroguaiaretic acid (NDGA). Said products are intended for all types of cosmetic and...

20060239956 - Preparation and use of hydrogels: The present invention pertains to a method for preparing a hydrogel in dry conditions that contains high loading of the active ingredient, preferably flavor or fragrance molecules. The hydrogel compositions are initially in solid form and preferably extruded and sized to form the desired shape and size. The actual hydrogel...

20060239958 - Biodegradable and pressure-sensitive material for medical use: Disclosed is a two-component, bio-degradable/absorbable adhesive medical material, which has a bonding component comprising a biodegradable polymer, and a hardening component comprising a low-molecular-weight derivative prepared by modifying a carboxyl group in a di- or tri-carboxylic acid of the citric acid cycle, with an electron-attracting group (one or a combination...

20060239959 - Method for treating hypercholesterolemia with polyallylamine polymers: s

20060239960 - Polymer-based compositions and conjugates of antimicrobial agents: Provided herein are water-soluble polymer conjugates and polymer-based compositions of antimicrobial agents. Also provided are methods for synthesizing and administering such conjugates and compositions....

20060239961 - Hydrolytically degradable alkylene oxide based polymers: The present invention provides a water soluble, nonpeptidic polymer comprising two or more alkylene oxide-based oligomers linked together by hydrolytically degradable linkages such as carbonates. Typically, the oligomer portion of the polymer is an amphiphilic triblock copolymer having a central propylene oxide block or butylene oxide block positioned between two...

20060239965 - Extracellular matrix binding chimeric proteins and methods of use thereof: The present invention provides chimeric polypeptides comprising a first polypeptide that binds to a component of extracellular matrix and a second polypeptide that provides for a therapeutic effect. The present invention further provides compositions, including pharmaceutical compositions, comprising a subject chimeric polypeptide. A subject chimeric polypeptide is useful in a...

20060239963 - Quil a fraction with low toxicity and use thereof: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can...

20060239962 - Rapid one-step generation of antigen loaded dendritic cell vaccine from precursors: A one-step method for producing antigen loaded antigen-presenting cells from monocytes ex vivo has been found which comprises contacting the monocytes with a composition comprising an activator such as TNF alpha preferably in combination with at least one growth factor such as GM-CSF and at least one soluble or particulate...

20060239964 - Retinal degeneration: Methods of treating a retinal degenerative disorder....

20060239976 - 75k rna regulated transcription: A method for altering transcription in a cell comprising an amount of active CDK9/cyclin, comprises the steps of: (a) introducing in the cell an agent which modulates the amount of active CDK9/cyclin in the cell, and thereby alters transcription in the cell, wherein the agent comprises an RNA selected from...

20060239972 - Adiponectin gene therapy: Adiponectin cDNA was cloned into AAV serotypes 1, 2, and 5-based expression vectors. Virions containing these vectors were administered to the livers of rat subjects via portal vein injection. A single injection of 6×1011 virions of the vector caused a sustained and statistically significant reduction in body weight of the...

20060239968 - Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer: The present invention concerns compositions comprising and methods of identification and use of targeting peptides selective for cancer tissue, particularly prostate or ovarian cancer tissue. The method may comprise identifying endogenous mimeotopes of such peptides, such as GRP78, IL-11Rα and hsp90. Antibodies against such targeting peptides or their mimeotopes may...

20060239974 - Enhancing cell migration by increasing telomerase activity: It has been discovered that increasing telomerase activity in cells surrounding a wound promotes wound healing. Replication capacity is enhanced, and the mobility of the epithelial cells can be increased by 3-fold or more. Particular aspects of the invention described in this disclosure include the use of agents that increase...

20060239970 - Herpesvirus amplicon particles: The invention includes methods for delivering therapeutic agents to a patient through administration of herpesvirus amplicon particles generated by a cell that stably express herpes simplex virus (HSV) immediate early 3 (IE3) gene....

20060239966 - In vivo gene therapy of parkinson's disease: The present invention concerns methods and compositions for gene therapy, in particular in vivo gene therapy for delivery of bioactive Neurturin for the treatment of Parkinson's Disease. In another aspect the invention relates to virus expression constructs comprising a mammalian signal peptide linked to a mature or N-terminally truncated Neurturin...

20060239973 - Methods and compositions for the treatment of ocular diseases: Methods and compositions for the tretament of ocular disease with a cyclin dependent kinase inhibitor are provided....

20060239975 - Methods for treating cancers and restenosis with p21: The p21 gene encodes a cyclin dependent kinase inhibitor which affects cell cycle progression, but the role of this gene product in altering tumor growth has not been established. The present inventors have now discovered that the growth of malignant cells in vivo is inhibited by expression of p21. Expression...

20060239967 - Oncolytic virus replicating selectively in tumor cells: By using a virus having a gene sequence comprising a telomerase promoter and an E1 gene (preferably a sequence comprising E1A gene, IRES sequence and E1B gene) or by using an anticancer agent comprising the virus, the virus replicates in cancer cells to thereby produce an efficient anticancer effect....

20060239969 - Rhesus her2/neu, nucleotides encoding same, and uses thereof: Polynucleotides encoding rhesus monkey HER2/neu have been isolated, cloned and sequenced. The gene encoding the HER2/neu is commonly associated with the development of epithelial-derived human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the HER2/neu tumor-associated antigen, wherein aberrant...

20060239971 - Vectors for regulating gene expression: The present invention pertains to vectors for regulating gene expression having at least one gene expressing cassette and at least one gene suppressing cassette, wherein the gene expression cassette encodes a polypeptide of interest, and wherein the gene suppressing cassette encodes a short interfering RNA (siRNA) molecule that reduces expression...

20060239985 - Method of preparing cell for transplantation: The invention features a method of producing cells for transplantation into myocardial tissue of a mammal and a method for treating a disorder using the cells. The method comprises the steps: (a) providing bone marrow stem cells that have not been immortalized; (b) culturing said bone marrow stem cells in...

20060239984 - Promoter to il-18bp, its preparation and use: The present invention relates to the promoter of interleukin-18 binding protein (IL-18BP), to its preparation and use....

20060239977 - Sustained release microbial insect control composition and means: Effective sustained release of microbial pesticides in aquatic environments can be achieved by the combination of buoyant particles with a particulate microbial active ingredient. The resulting materials in the form of a particulate have combined density of less than one. The materials are then dispersed into gypsum slurry that is...

20060239981 - Bioreactor system and method of enhancing functionality of muscle cultured in vitro: A method of producing organized skeletal muscle tissue from precursor muscle cells in vitro comprises: (a) providing precursor muscle cells on a support in a tissue media; then (b) cyclically stretching and relaxing the support at least twice along a first axis during a first time period; and then (c)...

20060239980 - Cartilage-derived stem cells and applications thereof: The invention relates to methods of isolating adult stem cells, to the cells thus isolated and to applications thereof. More specifically, the invention relates to isolated adult stem cells, which are derived from dedifferentiated chondrocytes, which can be differentiated and which can give rise to a series of cell lineages,...

20060239982 - Debulking catheters and methods: A debulking catheter comprising a tissue debulking assembly for removing a continuous strand of material from a body lumen. Catheters of the present invention generally include a catheter body having proximal and distal portions and a tissue debulking assembly disposed at least partially within the distal portion. The tissue debulking...

20060239979 - Dendritic cell presenting a-glycosylceramide derivative and antigent and usable in suppressing immune response: The present invention relates to dendritic cell and cell mixture which is capable of suppressing T cell-dependent immune response specific for an antigen. The dendritic cell according to the present invention is a dendritic cell capable of suppressing T cell-dependent immune response specific for an antigen, which presents antigen fragment...

20060239978 - Gene expressed specifically in dopamine-producing neuron precursor cells after termination of division: A novel gene 65B13 expressed specifically and transiently in dopaminergic neuron precursor cells immediately after cell cycle exit was obtained by the present invention. The cellular expression of 65B13 can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network...

20060239983 - Methods and compositions for the repair and/or regeneration of damaged myocardium: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration cytokines are disclosed and claimed. Methods and compositions for the development of large arteries and vessels are also disclosed and claimed. The present application also discloses and claims methods and media for the growth, expansion, and...

20060239986 - Method for the formation of hydrogel multilayers through surface initiated photopolymerization: Multiple-layer hydrogels and methods of forming hydrogels having multiple layers are disclosed. The hydrogels are formed of prepolymerization solutions comprising monomers or macromers, particularly polyethylene glycol. The layers are covalently bonded, and the hydrogels may comprise two or more layers....

20060239987 - Nutritional composition and methods of making and using same: A composition and method for treatment and/or prophylaxis of stressed-induced conditions and a method of forming the composition are disclosed. The composition includes hyaluronic acid and superoxide dismutase configured to mitigate denaturing of the superoxide dismutase in a digestive track of an animal. Mitigating the denaturing of the superoxide dismutase...

20060239989 - Glutamine:fructose-6-phosphate amidotransferase(gfat) comprising an internal purification marker and use thereof for the screening of compounds: The invention relates to a protein with enzymatic activity, comprising a GFAT sequence and at least one sequence of a purification marker, the sequence for the purification marker being inserted between two consecutive amino acids of the GFAT sequence....

20060239988 - Neuronal regeneration and compound administration methods: A method of modulating growth of an axon is disclosed. The method comprises regulating importin mediated retrograde transport in the axon....

20060239990 - Protein arginine n-methyltransferase 2 (prmt-2): The invention provides insight into the function of Protein Arginine N-Methyltransferase-2 (PRMT-2) and provides methods for modulating PRMT-2 activity or expression in cells. The methods of the invention can be used to inhibit the function of NFκB, E2F1 and STAT3 and have utility for treating a variety of conditions including,...

20060239991 - Novel trna synthetase: The invention provides tRNA synthetase polypeptides and DNA (RNA) encoding tRNA synthetase polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tRNA synthetase polypeptide for the protection against infection, particularly bacterial infections....

20060239992 - Methods and compositions for the inhibition of growth of infectious aspergillus fumigatus and other mycotic organisms in the gut of mammalian and avian species: A method for the prevention and treatment of fungal infections and, therefore, consequent invasive mycosis in mammalian and avian species is described. The invention comprise a combination of β-1,3(4)-endoglucanohydrolase, β-1,3(4)glucan, diatomaceous earth, mineral clay, and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient...

20060239993 - Drug containing angiotensin convertase: The medicine containing angiotensin-converting enzyme or its peptidase-inactivated mutants that specifically releasing GPI-anchored proteins from the cell surface, for preventing or curing diseases, such as prion-related diseases, inflammatory diseases, bacterial infectious diseases and male infertility due to sperm-egg binding insufficiency....

20060239994 - Novel serine protease bssp4: There are provided proteins having the amino acid sequences represented by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20; proteins having amino acid sequences derived from these amino acid sequences by deletion, substitution or addition of one to several amino acids; and nucleotide sequences...

20060239995 - Silk firing product, antibacterial material using the same and process for producing the silk firing product: The present invention provides a novel silk burned product. The silk burned product of the present invention is characterized by the step of burning and carbonizing a silk material at temperature of 1,000° C. or below. By burning at low temperature, nitrogenous components derived from amino acids remain in high...

20060239996 - Antibodies specific for ungulate prp: The present invention provides antibodies that specifically bind with a high degree of binding affinity to a native ungulate PrPC and/or a denatured ungulate PrPSc, but not to a native ungulate PrPSc. Preferred antibodies find native bovine PrPC and treated PrPSc but not native bovine PrPSc and can be used...

20060239997 - Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of...

20060239998 - Anti-idiotypic antibodies against factor viii inhibitor and uses thereof: The present invention discloses anti-idiotypic antibodies and fragments thereof against inhibitory Factor VIII anti-bodies, said inhibitory antibodies having an affinity for the C2 domain of Factor VIII. The anti-idiotypic antibodies of the present invention are able to completely neutralise in vitro and in an in vivo mouse model the inhibitory...

20060240000 - Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound: Pharmaceutical composition comprising an anti-IgE antibody and at least one further antiallergic compound selected from the group consisting of anti-inflammatory agents, leukotriene modifiers, bronchodilators, antihistamines, interleukin antagonists, mast cell inhibitors, and immunotherapeutical agents, such as 33-epichloro,33-desoxyzascomycin (pimecrolimus), in which the active ingredients are present in each case in free form...

20060239999 - Preventive and/or therapeutic drugs for asthma: a

20060240001 - P-cadherin antibodies: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates...

20060240003 - Humanised antibodies to the epidermal growth factor receptor: The present invention provides a humanised form of the antibody 340 obtainable from the cell line deposited with the ECACC under accession number 97021428. Such antibodies have been found to have an increased ability to kill cells compared to the murine antibody 340. Also provided are nucleic acids encoding such...

20060240002 - Methods of inhibiting angiogenesis-dependent conditions mediated by cryptic epitopes of extracellular matrix components: The invention provides methods for identifying genes and proteins modulated by an antagonist to a cryptic epitope of an ECM component that specifically binds to the ECM component. It additionally provides methods for using the products of the identified genes, or for using the identified proteins, for inhibiting angiogenesis, tumor...

20060240004 - Methods for treating tweak-related conditions: The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that...

20060240009 - Liposome composition for improved intracellular delivery of a therapeutic agent: A liposomal composition and a method of using the same for achieving intracellular delivery of a liposome-entrapped agent is described. The liposomes are composed of a pH sensitive lipid and include a targeting ligand to direct the liposomes to a target cell. The liposomes also include a stabilizing component, such...

20060240007 - Method for treating dementia or alzheimer's disease: Methods for treating Alzheimer's disease (AD) or dementia using a CD20 antibody are described. Articles of manufacture for use in such methods are also described....

20060240005 - Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells: The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeutic antibody in combination with alloreactive natural killer cells in order to enhance...

20060240010 - Methods of modulating cd200 receptors: Provided are methods for modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders....

20060240006 - Novel antibody structures derived from human germline sequences: In order to provide necessary information for the production of complete human monoclonal antibodies capable of human CD152 (CTLA-4) binding, the primary structures of heavy and light chains have been elucidated. The novel amino acid sequence of identified heavy and light chains are derived from VH3 and Vλ germline genes,...

20060240008 - Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor: The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor....

20060240016 - Activity of thap-family chemokine-binding domains: Described herein are chemokine-binding domains of THAP-family polypeptides and pharmaceutical compositions which include a polypeptide comprising a chemokine-binding domain of a THAP-family polypeptide. Also disclosed are methods of binding chemokines, inhibiting the activity of chemokines, detecting chemokines, and reducing the symptoms associated with a chemokine mediated or influenced condition by...

20060240018 - Artificial antibody polypeptides: A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of...

20060240013 - Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37): The invention provides a human BG37 which is associated with the disorders of the gastroenterology system, disorders of the peripheral and central nervous system, urology diseases, hematology diseases, cancer diseases, inflammation and cardiovascular diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention...

20060240017 - Human anti-tnf antibodies and peptides: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of...

20060240012 - Human antihuman interleukin-6 antibody and fragment of antibody: A substance effective for treating immunopathy where interleukin 6 (IL-6) is involved is provided. A human anti-human IL-6 antibody and a human anti-human IL-6 antibody fragment having a high affinity to human IL-6 were obtained using phage antibody technique. Said antibody and antibody fragment are expected to be useful as...

20060240014 - Methods and compounds for the treatment of vascular stenosis: This invention features a method of treatment for vascular stenosis or restenosis using a combination of N-phenyl-2-pyrimidine derivatives such as imatinib mesylate and PI3K inhibitors, such as rapamycin....

20060240015 - Recombinant antibody against human insulin-like growth factor: It is demanded that pharmaceutical agents for therapeutic treatment of diseases such as cancer, acromegaly and diabetic complications, of which IGF is involved in the progress of the conditions. The present invention provides a recombinant antibody or an antibody fragment thereof which specifically binds to human insulin-like growth factor-I (hereinafter...

20060240011 - Use of nf-kappa b inhibitors for the treatment of mastitis: The present invention relates to the use of NF-KB (NF-kappa B) inhibitors for the manufacture of a medicament for the treatment of mastitis....

20060240019 - Antagonists of hmg1 for treating inflammatory conditions: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring...

20060240020 - Inhibition of complement activation: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including...

20060240023 - Apoptosis-associated protein and use thereof: The present invention provides a partial peptide comprising the functional domain of a protein comprising an amino acid sequence which is the same or substantially the same as an amino acid sequence represented by SEQ ID NO:2 or SEQ ID NO: 4; a screening method and a kit therefor for...

20060240022 - Factor involved in metastasis and uses thereof: The present invention is related to a nucleic acid coding for a factor involved in a biological process, whereby the process is a PI 3-kinase pathway regulated process, preferably a process selected from the group comprising glucose metabolism, amino acid and glucose deprivation processes, diabetes, wound healing, stress response, apoptosis,...

20060240027 - Individualized anti-cancer antibodies: The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used...

20060240021 - Mammalian genes involved in rapamycin resistance and tumorgenesis: rapr7 genes: The invention provides nucleotide sequence of a novel mammalian gene which is involved in rapamycin resistance and tumorgenesis the RapR7 gene, and amino acid sequences of its encoded proteins, and fragments and derivatives and analogs thereof. The present invention also provides methods and compositions for regulating rapamycin resistance and/or tumorgenesis...

20060240026 - Preventing and/or remedy hematopoietic tumor: In the present invention, a useful molecular target for a specific immunotherapy of hematologic malignancies was found, and a means capable of preventing and/or treating hematologic malignancies was provided. Specifically, provided were the followings: an agent for preventing and/or treating hematologic malignancies comprising as an active ingredient at least one...

20060240025 - Rtvp-glipr-like compositions and methods for the detection, treatment and prevention of prostate cancer: The invention is directed to purified and isolated novel RGL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above....

20060240024 - T cell regulation: Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating...

20060240028 - Anti-nls substances and uses thereof in nuclear import inhibition: The present invention relates to a substance that specifically binds a nuclear localization signal (NLS)-containing molecule. Said substance may be a naturally occurring, synthetic or recombinant antibody, or it may be a protein, a peptide or a small molecule. Preferably, said NLS-containing molecule is a HIV-1 protein, more preferably Vpr...

20060240029 - Chlamydia pneumoniae antigens: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from C. pneumoniae, methods for isolating such antigens and specific uses thereof....

20060240030 - Anti-hiv immunogenic formulation and process for preparation thereof: A process is disclosed for preparation of a immunogenic peptide mixture in a single synthesis. The peptide mixture collectively represents the in vivo variability seen in immunogenic epitopes from an HIV pathogen. The mixture is termed a hypervariable epitope construct (HEC). Immunization with a HEC evokes broadly reactive immunity against...

20060240032 - Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases: A composition and method for treating an autoimmune condition are disclosed. The composition includes of an immunomodulating compound composed of a central amino acid core having a plurality of chemical attachment groups, and a plurality of antigenic peptides which are (i) associated with an auto-immune disorder and (ii) attached to...

20060240031 - T cell receptor cdr3 sequences and methods for detection: The present invention relates generally to the field of treating autoimmune diseases, such as multiple sclerosis (MS), rheumatoid arthritis (RA) and others. Methods of treating and monitoring an autoimmune disease by utilizing T-cell receptors peptides are disclosed. Nucleic acid and peptide sequences of T-cell receptors found in a population of...

20060240033 - Use of allogenic or syngenic major histocompatibility complex (mhc) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease: The present invention is directed to the discovery that allogenic or syngenic adjuvant stimulation can cause local inflammation which increases the antigen presentation capability of cells in the vicinity of adjuvant stimulation. By discovering this phenomenon, the present invention provides a novel method for augmenting the immunogencity of an antigen...

20060240034 - Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats: The invention concerns a vaccine that can induce protection against disease especially in consequence of a lentivirus infection, especially an infection with the Feline Leukosis virus. Such vaccine comprises codon-optimized DNA sequences encoding structural proteins and the most important membrane protein of FeLV....

20060240035 - Vmp-like sequences of pathogenic borrelia species and strains: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis....

20060240036 - I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and cd-95 induced apoptosis: The present invention relates to a novel I-FLICE-1 or I-FLICE-2 protein which is a novel inhibitor of TNFR-1 and CD-95 induced apoptosis. In particular, isolated nucleic acid molecules are provided encoding the human I-FLICE-1 or I-FLICE-2 protein. I-FLICE-1 or I-FLICE-2 polypeptides are also provided as are vectors, host cells and...

20060240037 - Methods and compositions for the treatment and prevention of degenerative joint disorders: The present invention features methods and compositions for the treatment, reduction, and prevention of degenerative joint disorders by administering to a mammal a joint enhancing composition. According to this invention, the composition increases the level of expression and secretion of endogenous lubricin such that the joints in the mammal being...

20060240038 - Cells used as carriers for bacteria: The invention relates to the use of a cell, which is charged with a micro-organism that contains foreign DNA, in particular a bacterial micro-organism, to produce a pharmaceutical composition. Preferably, the foreign DNA codes for a defined active agent and the pharmaceutical composition is designed for use in the prophylaxis...

20060240040 - Optimized expression of hpv 45 l1 in yeast: Synthetic DNA molecules encoding the HPV45 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV45 L1 protein, wherein said polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV45 virus-like particles (VLPs), and to produce vaccines...

20060240041 - Prrsv vaccines: The invention relates to the field of PRRS viruses and infectious clones obtained from PRRS viruses. Furthermore, the invention relates to vaccines and diagnostic assays obtainable by using and modifying such infectious clones of PRRS viruses. The invention provides a porcine reproductive and respiratory syndrom virus (PRRSV) replicon having at...

20060240039 - Vaccines: The present invention relates to a vaccination comprising co-administration of an antigen and viral vector providing immunity at both humoral and antibody levels....

20060240042 - Immunogenicity using a combination of dna and vaccinia virus vector vaccines: This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly...

20060240043 - Methods and compositions for treating migraine pain: The present invention provides novel methods and compositions for the treatment and prevention of headaches, vascular headaches, migraine headaches, cluster headaches, and migraine. One of the headaches, vascular headaches, migraine headaches, cluster headaches, and migraine treated by the methods and compositions of the invention is migraine....

20060240044 - Streptococcal superantigens spe-l and spe-m: The invention provides superantigens SPE-L and SPE-M, and their functional equivalents. In addition, the invention relates to nucleic acid molecules encoding the superantigens and/or their functional equivalents, and variant nucleic acids. The invention also provides diagnostic and therapeutic applications based on such superantigens and nucleic acid molecules....

20060240045 - Neisserial vaccine compositions comprising a combination of antigens: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane...

20060240046 - Live attenuated leishmania vaccines: Targeted disruption of the centrin gene leads to attenuation of growth in Leishmania. Preferred embodiments of the invention provide attenuated strains of Leishmania useful for the preparation of immunogenic preparations including vaccines against a disease caused by infection with a virulent Leishmania strain and as tools for the generation of...

20060240047 - Method for producing a vaccine for the treatment of cancer: The present invention discloses a method for producing a haptenized vaccine from a tissue biopsy. The method includes obtaining a tissue biopsy, isolating the cells, irradiating the cells, haptenizing the cells, and cryopreserving the cells. The present invention also discloses a method for treating cancer using the vaccines produced by...

20060240048 - Pyridine derivatives as cb2 receptor modulators: The present invention relates to novel pyridine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor....

20060240049 - Anti-protozoal compositions comprising diclazuril: The present invention relates to compositions suitable for oral, transdermal or parenteral (e.g. intranasal, intramuscular, subcutaneous or intravenous) administration, wherein the composition is comprised of at least one anti-protozoal agent dissolved in a mixture of an alcohol based solvent-system, an emulsifier-system and a base-system. Also provided is a method for...

20060240051 - Eutectic blends containing a water soluble vitamin derivative: An eutectic composition having from about 10 to about 90 weight % of a first component comprising a pharmaceutically acceptable substituted C6-C10 aryl compound wherein the aryl moiety includes a straight or branched moiety selected from the group consisting of C1-C12 alkyl, C1-C12 alkoxy, C2-C6 alkanoyloxy, hydroxy, carboxy, carboxy substituted...

20060240052 - Ketoprofen compositions and methods of making them: A wide variety of pharmaceutically and commercially acceptable dosage forms of ketoprofen are prepared by dissolving ketoprofen in pharmaceutically acceptable solvents....

20060240050 - Stable clozapine suspension formulation: A physicochemically stable aqueous composition including clozapine suspension....

20060240054 - Irritant-free gel compositions: Irritant-free gel compositions according to the present invention include less than 5 parts by weight of one or more marking agents, 0.25-2 parts by weight of a thickening agent; and 30-90 parts by weight water. The thickening agent is typically a vegetable gum. In some embodiments, the compositions may additionally...

20060240055 - Perfume composition having sedative effect: The present invention provides a perfume composition, which comprises at least one trimethoxybenzene in an amount of less than 0.5% by weight based on the total weight of the perfume composition. The present invention also provides a method for providing sedation in a subject, which comprises applying a perfume composition...

20060240056 - Treatment of skin with adenosine or adenosine analog: Methods for enhancing the condition of non-diseased skin by application of compositions containing adenosine or an adenosine analog are disclosed. Also disclosed are methods for increasing DNA synthesis or protein synthesis in dermal cells, and methods for increasing dermal cell size, by application of compositions containing adenosine....

20060240053 - Use of aspartic proteases in cosmetics and therapeutics: The invention provides a cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, at least one purified natural or synthetic polypeptide wherein the peptide sequence is represented wholly or partly by at least one sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 4,...

20060240057 - Termiticide compositions: Termicidal compositions comprising bifenthrin and acetamiprid are disclosed. The compositions provide a combination of properties not exhibited by either active ingredient when used alone....

20060240058 - Combinatorial surface chip compositions for selection, differentiation and propagation of cells: A combinatorial library high-throughput technique for varying polymer surface structures has been developed that allows rapid, efficient, and accurate investigation of the effects of microstructure, roughness, and surface chemistry on stem cell adhesion, proliferation and differentiation. Bloactive molecules, such as cytokines, growth factors, and extracellular matrix components can be attached...

20060240060 - Lubricious compound and medical device made of the same: The present invention includes a lubricious polymer blend wherein at least one of the polymer materials is a water insoluble polymer and one of the materials is a lubricious water-soluble polymer. The invention includes a method of forming a desired medical device by melt mixing the selected polymers and then...

20060240059 - Lubricious eluting polymer blend and coating made from the same: The present invention relates to a drug eluting polymer blend. More particularly, the present invention relates to a medical device with a drug eluting polymer blend incorporated therein wherein the drug elution rate is controlled by cross-linking the polymer blend. Once formed, the polymer blend can be used to create...

20060240061 - Tissue engineered blood vessels: The invention is directed to methods for preparing artificial blood vessels by preconditioning a matrix seeded with endothelial cells to fluid flow conditions that mimic blood flow....

20060240067 - Biocompatible articles and related methods: Biocompatible articles and related methods are disclosed....

20060240069 - Catheter assembly with bactericidal effect: A use in a medical device of at least one salt of organic acid(s), and preferably a benzoate or a sorbate, as an antimicrobial agent is disclosed, and in particular for the manufacturing of an antimicrobial coating for a medical device for the prevention of bacterial infection. This is very...

20060240065 - Compositions for medical devices containing agent combinations in controlled volumes: The present invention generally encompasses controlled-volume materials that may, for example, be in a medical device or applied on a medical device as a coating, as well as methods of applying these materials....

20060240066 - Elastin stabilization of connective tissue: A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm...

20060240063 - Medical implants and fibrosis-inducing agents: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue....

20060240064 - Medical implants and fibrosis-inducing agents: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue....

20060240062 - Metal implant coated under reduced oxygen concentration with osteoinductive protein: The present invention relates to a method for producing a device comprising the steps of (a) providing a solution comprising dissolved osteoinductive protein, (b) contacting the solution of the preceding step with a carrier containing a surface of metal or a metal alloy, (c) allowing coating of the surface of...

20060240068 - Pharmaceutical composition as solid dosage form and method for manufacturing thereof: The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a...

20060240072 - Crosslinkable macromers: A crosslinkable macromer system and related methods of preparing the system and using the system in the form of a crosslinked matrix between a tissue site and an implant article such as a tissue implant or on the porous surface of a prosthetic device. The macromer system includes two or...

20060240070 - Delivery of highly lipophilic agents via medical devices: An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000,...

20060240071 - Non-hormonal vaginal contraceptive: An intravaginal contraceptive device has a biocompatible support structure constructed and configured to be inserted into a mammal's vagina without substantially blocking the cervix, coated by a multilayer coating having one or more biodegradable polymers. The multilayer coating can be constructed and formed of materials such that the multilayer coating...

20060240073 - Structure of modulating intraocular pressure on glaucoma: A 3D porous structure is designed for modulating intraocular pressure on glaucoma. The 3D porous structure includes collagen and glycosaminoglycan in the form of copolymer, wherein the collagen and the glycosaminoglycan have a 10:1 ratio in weight and the copolymer has a percentage in the range of 0.125% to 8%....

20060240075 - Carnitine retention: A composition for influencing carnitine retention in biological tissue is disclosed. The composition comprises a carnitine substance and an agent to increase sodium potassium ATPase pump activity in the tissue, and/or to increase the activity of a carnitine transport protein, and/or increase blood/plasma insulin concentration....

20060240074 - Novel triple mineral salts of (-)-hydroxycitric acid and processes for preparing the same: This invention also includes a process for preparing the triple salts by adding stiochiometric amounts of aqueous solutions of the compounds of the desired metal to an aqueous solution of (−)-HCA. Preferably an extract from garcinia fruit ring is used as a starting material. Compounds of this invention are substantially...

20060240076 - Preparation and use of hydrogels: The present invention pertains to a method for preparing a hydrogel in dry conditions that contains high loading of the active ingredient, preferably flavor or fragrance molecules. The hydrogel compositions are initially in solid form and preferably extruded and sized to form the desired shape and size. The actual hydrogel...

20060240078 - Feed supplement delivery system: Disclosed are novel feed supplements for ruminants and methods for making the same. The feed supplements include unsaturated fatty acid encapsulated by a protective coating. Through utilization of the disclosed feed supplements, dietary intake and absorption of unsaturated fatty acids can be increased, due to protection of the ingested unsaturated...

20060240079 - Method for making insect repellent composition: Dihydronepetalactone, a minor natural constituent of the essential oil of catmints (Nepeta spp.) such as Nepeta cataria, has been identified as an effective insect repellent compound. Synthesis of dihydronepetalactone may be achieved by hydrogenation of nepetalactone, the major constituent of catmint essential oils. This compound, which also has fragrance properties,...

20060240077 - Methodologies for improving the quality of meat, health status of animals and impact on environment: Disclosed is a method and a product of a chicory root product for reducing taint in animals, said method comprising feeding to an animal a chicory root product during at least one day prior to slaughtering the animal. By feeding animals with the chicory root product this improves the quality...

20060240080 - Alginate sponge and preparation method thereof: The present invention relates to an alginate sponge and a preparation method thereof, more particularly to an alginate sponge having significantly improved flexibility, structural integrity, water-absorptivity, and processability, to be used for medical and tissue engineering purposes, and a simple preparation method thereof. The alginate sponge of the present invention...

20060240082 - Method for manufacture of improved cleaning and washing products: A method for creation of an improved cleaning product having an antimicrobial composition integrated therein....

20060240081 - Pack-a-poof: A disposable apparatus for body cleansing comprising a preselected material, which exhibits both flexible, softness and porous properties, formed into a predetermined shape and a cleansing material at least one of disposed on and disposed within and retained by said preselected material....

20060240083 - Antimicrobial and immunostimulating composition: A medical composition comprising an antimicrobially effective and immunostimulating amount of a combination of a β-glucan component and a silver-containing component is disclosed. The medical composition may be adapted for use topically or incorporated with a mesh material which may be further adapted for use as a wound dressing or...

20060240084 - Microbial cellulose materials for use in transdermal drug delivery systems, method of manufacture and use: A method for transdermally delivering a biologically active agent to a subject in need thereof, comprising topically applying a composition comprising insoluble microbial cellulose, water, and a therapeutically effective amount of the biologically active agent, wherein the biologically active agent penetrates through the subject's stratum corneum at a substantially constant...

20060240086 - Adhesive patch: An adhesive patch which includes a pressure-sensitive adhesive layer comprising a composition which comprises: bisoprolol and/or a pharmaceutically acceptable salt thereof; and an acrylic polymer obtained by copolymerizing a (meth)acrylic ester with a carboxylated (meth)acrylic acid. The adhesive patch is stable and excellent in penetration through the skin....

20060240087 - Composition and methods for drug delivery: A dermal composition for administration of a drug comprising a blend of two or more acrylic-based polymers having differing functionalities so as to modulate the drug solubility in the polymer matrix and the delivery rate of the drug, and methods therefor....

20060240085 - Treatment of dependence withdrawal: Dosage regimens of buprenorphine to treat withdrawal or abstinence syndrome in a drug dependent or opioid tolerant patient who is pregnant are described. The method includes treating withdrawal or abstinence syndrome of the patient by transdermal administration of an amount of buprenorphine effective to reduce withdrawal symptoms. For example, a...

20060240088 - Caged ligands and uses thereof: Provided are caged compounds comprising a ligand that specifically reacts with a receptor not naturally present in mammals. The cage is released from the ligand upon illumination of the compound with light. Also provided are cells transfected with a gene of interest and a gene encoding a receptor, the gene...

20060240090 - Combination compositions of camptothecins and fluoropyrimidines: Compositions which comprise liposomes having stably associated therewith a camptothecin and a fluoropyrimidine are useful in achieving enhanced therapeutic effects when combinations of these drugs are administered....

20060240093 - Lipid encapsulated interfering rna: The present invention provides compositions and methods for silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell....

20060240091 - Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof: A novel targeting peptide from the C-terminal of endothelin and/or a novel fusogenic peptide from hemagglutinin are optionally conjugated to the carboxy group of 1,2-dioleoyl-sn-glycero-3-succinate and incorporated into liposomes for therapeutic treatment. The novel targeting peptide directs liposomes to lung cells, and, therefore, is useful for delivering liposomes encapsulating cholinesterase...

20060240092 - Polymeric micelles for drug delivery: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same....

20060240089 - Use of pvp-iodine liposomes for treatment of herpes: The invention concerns a method for the production of a pharmaceutical preparation for the treatment of Herpes forms that is characterized in, that the preparation comprises at least one anti-septic compound associated with a particular carrier....

20060240096 - Devices and methods for treating the gastrointestinal system: Devices and methods for less invasively treating the gastrointestinal system, such as the intestinal mucosa of the small bowel. Embodiments described herein may be used to reduce caloric absorption and effectuate weight loss, for example....

20060240094 - Masticatable capsule and process for producing the same: This chewable capsule has an encapsulating shell and a filling contained within the encapsulating shell, in which outer diameter of the above encapsulating shell ranges from 14 mm to 25 mm, and mass of the above encapsulating shell ranges from 10% to 20% of the total mass of the chewable...

20060240095 - Pharmaceutical composition comprising a combination of metformin and a statin: A pharmaceutical composition comprising: (i) metformin, optionally in the form of one of its pharmaceutically acceptable salts, (ii) a statin, optionally in the form one of its pharmaceutically acceptable salts, and optionally one or more pharmaceutically acceptable excipients, is suitable for use in the treatment of hyperglycemia non-insulin-dependent diabetes, dyslipidemia,...

20060240097 - Trpv1 agonist compounds and methods for making and using the same: Described here are TRPV1 agonist compounds and their methods of synthesis and use. In addition to specifically identified compounds, capsaicin prodrugs, gemini dimers, and mutual prodrugs are also described. Formulations of the TRPV1 agonist compounds may be in the form of a liquid, tablets, capsules, gel, cream, emulsion, a patch,...

20060240098 - Formulations for hyperforin-enriched hypericum fractions: St. John's Wort products which have enhanced bioactivity in a serotonin re-uptake assay and enhanced stability and bioavailability are formulated and manufactured from hyperforin-enriched Hypericum fractions made by supercritical and near critical fluids with and without polar cosolvents. These fluids are used to fractionate the biomass materials in several sequential...

20060240099 - High-amylose starch: The subject of the present invention is a process for preparing pregelatinized high amylose starch, having the steps consisting of: forming a suspension comprising a high amylose starch and water; subjecting the suspension to steam jet cooking at a temperature of between 125 and 135° C. so as to obtain...

20060240102 - Binders for tablets with high strength based on finely divided vinyllactam polymers, the production and use thereof: Finely divided binders in powder form composed of vinyllactam polymers, where the binders have an average particle size of up to 35 μm and an apparent density of less than 0.2 g/ml....

20060240100 - Dosage form containing pantoprazole as active ingredient: Dosage forms for the oral administration of the magnesium salt of pantoprazole are described....

20060240101 - Orally disintegrating pharmaceutical tablet formulations of olanzapine: This invention provides orally disintegrating pharmaceutical tablet formulations comprising per tablet the following ingredients in the following percentages by weight: olanzapine as an active ingredient in an amount from about 2.5% to about 10%; mannitol in an amount from about 75% to about 95%; a disintegrating agent in an amount...

20060240103 - Effervescent compositions comprising bisphosphonates and methods related thereto: The invention provides effervescent composition comprising a bisphosphonate, an acidic compound, an alkaline effervescing component, and optionally an anti-ulcer agent and methods of treating osteoporosis in a mammal using the effervescent compositions....

20060240104 - Controlled or sustained-release formulation: A formulation comprising: a co-polyester comprising (a) the reaction product of a polycondensation polyester and (b) glycolide; wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and ethylene glycol, and the co-polyester comprises about 40% by weight of the polycondensation polyester based on the...

20060240105 - Multiparticulate modified release composition: The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers at least one active ingredient in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of...

20060240108 - Cellulosic films incorporating a pharmaceutically acceptable plasticizer with enhanced wettability: An enteric coating for a solid pharmaceutical carrier or substrate wherein the enteric coating includes a cellulosic polymeric material selected from selected from the group consisting of hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, cellulose acetate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose acetate succinate, cellulose...

20060240107 - Controlled-release compositions: A solid dosage formulation having a core with a pharmacological agent dispersed in a first controlled-release matrix from which release of the agent is relatively slow; and a coat formed over the core and having the agent dispersed in a second controlled-release matrix from which release of the agent is...

20060240106 - Enteric coated composition comprising prostaglandin analogs as chloride channel opener: The present invention provides an enteric coated composition for oral administration of a chloride channel opener which can provide improved pharmaceutical activity with reduced adverse side effect such as nausea....

20060240109 - Cellulosic and lignocellulosic materials and compositions and composites made therefrom: Cellulosic or lignocellulosic materials, and compositions and composites made therefrom, are disclosed....

20060240110 - Multifunctional and biologically active matrices from multicomponent polymeric solutions: The present invention relates to a biologically active functionalized electrospun matrix to permit immobilization and long-term delivery of biologically active agents. In particular the invention relates to a functionalized polymer matrix comprising a matrix polymer, a compatibilizing polymer and a biomolecule or other small functioning molecule. In certain aspects the...

20060240111 - Semi-solid mucoadhesive formulations: Semisolid mucoadhesive formulations for vaginal application, with improved technical and organoleptic characteristics, which contain at least two bioadhesive gelling polymers and an active ingredient, useful in the prevention and/or treatment of various pathologies and disorders in human beings or animals....

20060240113 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions....

20060240112 - Process for the purification of riboflavin: The invention relates to a process for the purification of riboflavin comprising the steps of (a) precipitating a first crystalline form of riboflavin, (b) isolating the first crystalline form of riboflavin, (c) transforming the first crystalline form of riboflavin into a second crystalline form of riboflavin under conditions that decompose...

20060240114 - Drug for treating hemophilia and method of treating hemophilia using the same: A therapeutic product or drug for therapy of hemophilia may be produced by a simplified method including embedding genes of the blood clotting factors VIII (IX) for therapy of hemophilia in hollow nano particles obtained on expressing the protein having a particle forming function, such as hepatitis B virus surface...

20060240116 - Bioactive factors in wound healing topical compositions and methods: A topical composition for treating a cutaneous wound includes whole colostrum or one or more growth factors, as well as a base by which the whole colostrum or one or more growth factors are carried. The topical composition may also include, without limitation, immunomodulators, lactoferrin, enzymes, vitamins, minerals, amino acids,...

20060240115 - Composition against injection with and process for producting the same: The present inventors discovered that microfiltration retentates of whey, and products obtained by treating whey using centrifugation and/or ammonium sulfate precipitation, have the activity of inhibiting rotavirus infection....

20060240117 - Snake powder extract for treatment of cancer: The present invention relates to a pharmaceutical composition comprising snake powder that is derived from the Tzabcan “Crotalus durissus” rattlesnake. The snake powder is prepared by continuously baking the body of the rattlesnake until it completely dehydrates. Then, the dehydrated body is pulverized into a fine granular powder. The present...

20060240118 - Pharmacologically active strong acid solutions: A composition and therapeutic methods therefore for pharmacologically strong acid solutions comprising a mixture of strong and weak acids....

20060240119 - Pharmacologically active strong acid solutions: A composition and therapeutic methods therefore for pharmacologically strong acid solutions comprising a mixture of strong and weak acids....

20060240121 - Chemotherapeutic composition using nanocrystalline calcium phosphate paste: A method and composition are provided for treating cancer in a mammal. The method includes administering to a tumor site of the mammal an anticancer composition comprising a mixture of an anticancer agent and a nanocrystalline or poorly crystalline calcium phosphate paste, said paste comprised of one or more calcium...

20060240120 - Composition for lowering blood glucose: The present invention relates to a composition for lowering blood glucose, which contains a polyphenol extracted, isolated, and purified from green tea, and calcium, as active ingredients. The inventive composition shows a synergistic blood glucose-lowering effect by the green tea polyphenol and the calcium, and thus will be useful for...

20060240122 - Antiseptic solutions containing silver chelated with polypectate and edta: A liquid antiseptic and cleanser having improved long-term stability includes at least the following principal ingredients: deionized water; silver ion, polypectate, and ethylenediaminetetraaceticacid (EDTA). Presently preferred embodiments of the technology also include glycerine; 1,2-propanediol (a.k.a. propylene glycol); at least one surfactant from any of the families of alkylsulfates, sulfonates, alkanolamides,...

20060240123 - Pharmaceutical composition: A topical composition comprises at least 5 wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also...

20060240124 - Treatment of anemia: Methods for treating anemia in a subject are described that include administering N-glycolylneuraminic acid or a derivative thereof to the subject....

20060240125 - Composition for affecting weight loss: A composition for reducing the weight of a human. The composition is provided in the form of a capsule comprising an effective amount of capsaicin and/or analogs thereof, L-tyrosine, supplemental caffeine and/or and analogs thereof, green tea extract containing catechin and caffeine, and embodiments which include calcium. The invention is...

20060240126 - Compositions containing allium sativum linn. (garlic) naturally enriched with organic selenium compounds for nutritional supplementation: The invention discloses selenium enriched garlic compositions that are a safe and efficacious means of providing supplemental amounts of the essential trace mineral nutrient selenium, to humans and animals....

20060240127 - Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-phthyl)ethyl]acetamide, on its own or in association, in obtaining medicaments intended for the treatment of bipolar disorders, especially bipolar disorders of types I and II, and more especially bipolar disorders of type I....

20060240128 - Combined immediate release and extended release analgesic composition: The present invention pertains to an analgesic composition comprising an analgesic drug in an extended release form in combination with an analgesia-enhancing amount of a nontoxic N-methyl-D-aspartate receptor antagonist in an immediate release form....

20060240129 - Skin tissue regeneration promoters comprising ginsenoside rb1: The present invention provides efficacious preparations for intravenous administration, preparations for external or topical application to skin, preparations for external or topical application to mucosa or cosmetics comprising ginsenosides, in particular, ginsenoside Rb1 or its derivatives which are useful as skin tissue regeneration/reconstruction promoters or wound healing promoters; and it...

20060240130 - Methods for treating prostate cancer with herbal compositions: The inventive subject matter relates to methods for treating prostate cancer, comprising administration of a composition comprising therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of holy basil, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, huzhang, Chinese goldthread, and...

20060240131 - Process for effecting the relaxation of muscles of a human by means of fragrance: Described is a process for effecting the relaxation of a tensive back, shoulder or neck muscle of a human mammal for a substantial period of time. The process of our invention consists essentially of the step of continuously or periodically administering to said human mammal through inhalation over a stress...

20060233705 - Diagnosis by determination of hyperactivity or increased expression of members of cell signaling pathways: A non-invasive method for determining the presence or severity of a bodily disorder associated with hyperactivity or increased expression of a signal transduction protein, transcription factor, or protein kinase that is a member of the MAPK or GPCR pathways. A reagent that binds to such a signal transduction protein, transcription...

20060233704 - Prochelator for the preparation of radiometal labeled molecules having improved biological properties: Chelating compounds for labeling bioactive molecules with a radiometal, having general formula (I) in which: both Y groups may be positioned either trans as shown or cis; A is an effector molecule, such as a peptide, in particular octreotide, CCK, substance P, gastrine, a protein, in particular an antibody or...

20060233706 - Marked peptides having affinity for a phospholipid and uses: in which the amino acids J are chosen independently of each other from natural amino acids, or derivatives thereof, in such a manner that at least 50% of them are polar residues chosen from Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Lys, Orn, Pro, Ser, Thr and Tyr, the...

20060233708 - Peptide antagonists of tgf-beta family members and therapeutic uses thereof: This invention is drawn to methods of using peptide-based antagonists of TGF-beta to facilitate the healing of cutaneous wounds that includes burns, lacerations and scrapes. The administration of peptide TGF-beta antagonists to wounds results in reduced scarring, wound contraction and deposition of extracellular matrix components, and increased rates of re-epithelialization...

20060233707 - Process for producing an injectable medicament preparation: The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance...

20060233709 - Method for identifying novel treatments of inflammatory disease in the gut: Model fish and use thereof for screening for the presence of gut inflammatory disease, especially in zebrafish. Induction of the disease state and visualization of the gastrointestinal tract in living zebrafish. Visualization of the inflammatory state in vivo facilitates screening for compounds that can be used in treatment of inflammatory...

20060233711 - Method for treating conditions associated with fear memory: A method of treating conditions associated with fear memory in a mammal is provided which includes selective inhibition of a GluR6 receptor. Methods of screening for compounds useful to treat such conditions are also provided....

20060233710 - Prevention and treatment for gvhd: The present invention is to provide a method for avoiding specifically and preventively or therapeutically an organ injury in graft-versus host disease (GVHD), a preventive or therapeutic agent therefore, and a method for screening the preventive or therapeutic agent. By inhibiting the interaction between fractalkine and the chemokine receptor CX3CR1...

20060233713 - Gadolinium particle-based mri contrast agents: Compositions comprising purified gadolinium-exchanged carboxylate-alumoxane nanoparticles in an aqueous solution are provided for use as MRI contrast agents. Targeted imaging is provided by nanoparticles comprising surface-bound antibodies specific for biomolecules present in a patient....

20060233712 - Magnetic nanoparticles: Materials and methods for making small magnetic particles, e.g. clusters of metal atoms, which can be employed as a substrate for immobilising a plurality of ligands. Also disclosed are uses of these magnetic nanoparticles as therapeutic and diagnostic reagents, and in the study of ligand-mediated interactions....

20060233714 - Use of a volatile liquid at atmospheric pressure and ambient temperature for the production of pharmaceutical or biological compositions: A liquid which is a perfluorinated compound whose vapor pressure at 25° C. and atmospheric pressure is greater than or equal to 10,000 Pa (100 mbar) and whose boiling point is greater than or equal to 30° C. is used in the manufacture of a pharmaceutical and/or biological composition. The...

20060233715 - Compositions for nasal administration of drug: Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals....

20060233718 - Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route: The present invention relates to aerosols containing alprazolam, estazolam, midazolam or triazolam that are used in inhalation therapy. In a method aspect of the present invention, alprazolam, estazolam, midazolam or triazolam is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of alprazolam,...

20060233719 - Delivery of antidepressants through an inhalation route: The present invention relates to the delivery of antidepressants through an inhalation route. Specifically, it relates to aerosols containing an antidepressant that are used in inhalation therapy. In a method aspect of the present invention, an antidepressant is administered to a patient through an inhalation route. The method comprises: a)...

20060233717 - Delivery of compounds for the treatment of headache through an inhalation route: The present invention relates to the delivery of migraine headache drugs through an inhalation route. Specifically, it relates to aerosols containing migraine headache drugs that are used in inhalation therapy....

20060233716 - Pharmaceutical formulations: The invention relates to the use of a ternary agent that is a sugar ester to inhibit or reduce chemical interaction between an active ingredient substance and a carrier in a solid pharmaceutical formulation, wherein the active ingredient substance is susceptible to chemical interaction with the carrier and the ternary...

20060233721 - Foam containing unique oil globules: The present invention provides a foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable oil in water emulsion composition includes: an oil globule system, selected from the group consisting...

20060233720 - Sprayable oil-like formulations: This invention relates to transparent, sprayable cosmetic oil-in-water formulations that provide superior moisturization comparable to traditional oil formulations....

20060233722 - Antibacterial 5,5'-disubstituted 3,3'-dialkoxy-2,2'-dihydroxy-1,1'-biphenyl compounds and related methods: Also included in the invention are toothpastes or tooth gels that include at least one humectant; at least one abrasive compound; and an antibacterially effective amount of the compound represented by the structure of formula (I). Also provided are methods of inhibiting bacterial growth in the oral cavity of an...

20060233723 - Mouth and/or throat wash: A mouth and/or throat wash which comprises an aqueous solution produced by immersing a permeable sac containing a measured quality of a mix of potassium nitrate, activated charcoal and particulate sulphur in a measured quantity of boiling water. The sac is removed from the boiling water after a predetermined period...

20060233724 - Medicinal composition for peridontal pocket administration containing bisphosphonic acid derivative or its salt as the active ingredient: A pharmaceutical composition for being administered to periodontal pockets, comprising as an effective ingredient a bisphosphonic acid derivative, which has an excellent sustained-release property when locally administered, is disclosed. The pharmaceutical composition for being administered to periodontal pockets according to the present invention comprises a bisphosphonic acid derivative or a...

20060233728 - Cosmetic powder: Cosmetic powders which contain an N-mono long chain acyl basic amino acid and a particular α-aminolactam derivative are superior in spreadability on the skin and affinity to the skin upon application, and the lightness and moisture of the skin after application, as well as safety....

20060233727 - Film foaming hydroalcoholic foam: The present invention provides a foam composition comprising an active agent. In particular, the foam composition produces a water resistant, preferably very water resistant, film upon application....

20060233729 - Long-acting, chemical-resistant skin emollients, moisturizers, and strengtheners: The present invention relates to compounds that are two-part molecules, and compositions containing such compounds, in which one part is designed to become covalently bonded to the skin (bonding agent) and the other part (a characteristic use agent) is designed to impart some characteristic use, such as emolliency, moisturizing effect,...

20060233725 - Non-endocrine disrupting cytoprotective uv radiation resistant substance: Compositions for enhanced UV-protective agents that increase immuno-responsiveness by providing cytoprotective additives for mammalian skin by ensuring avoidance from endocrine disrupting agents are described. A composition comprising: (a) at least one inorganic non-endocrine disrupting sun-blocking agent or organic non-endocrine disrupting sunscreen agent, (b) at least one non-endocrine disrupting emollient or...

20060233726 - Spf scalp sun screen protector: The SPF Scalp Sun Screen Protector is the only product that will protect the scalp and the hair of an individual with fine or thinning hair from the ultra violet rays of the sun. It is a lotion that an individual can use on his scalp for outdoor events, such...

20060233733 - Detergent cosmetic compositions comprising three surfactants and at least one fatty ester, and use thereof: The present disclosure relates to novel detergent and conditioning compositions comprising, in a cosmetically acceptable medium, at least one sulfate or sulfonate anionic surfactant; at least one carboxylic anionic surfactant chosen from polyoxyalkylenated (C6-C24)alkyl ether carboxylic acids, polyoxyalkylenated (C6-C24)alkylaryl ether carboxylic acids and salts thereof, polyoxyalkylenated and (C6-C24)alkylamido ether carboxylic...

20060233734 - Hair treating agent: wherein R1 and R2 independently represent an alkyl or hydroxyalkyl group having 1 to 5 carbon atoms or —R8—COOH, R3, R4 and R8 independently represent an alkylene group having 1 to 5 carbon atoms, R5 represent an alkyl or hydroxyalkyl group having 1 to 5 carbon atoms or —R9—COOH and...

20060233735 - Method for treating ailments of the scalp: The invention concerns a foaming composition for washing and treating hair and/or scalp essentially characterised in that it contains in an aqueous medium: at least an active principle selected among corticoids and retinoids; at least an anionic surfactant; at least an amphoteric surfactant; and a pro-penetrating...

20060233736 - Cosmetic compositions containing mono-hydroxyl substituted amines and acid derivatives: Disclosed are cosmetic or dermatological compositions that include a mono-hydroxyl substituted amine such as dimethylaminoethanol (DMAE), a sulfonic, phosphoric, or phosphonic acid derivative, and a cosmetically acceptable carrier. Also disclosed are methods for making and using the compositions....

20060233730 - Hyperbranched polymers with low glass-transition temperature and uses thereof in cosmetics: The invention relates to a hyperbranched polymer comprising at least three polymer branches. Said branches form either the main branch or a secondary branch and each comprise at least one branch point which is at least trivalent in order to form at least two different and independent branch points which...

20060233732 - Keratin fiber coating composition comprising a continuous aqueous phase and at least one volatile oil: The present disclosure relates to a keratin fiber coating composition comprising a continuous aqueous phase and at least one volatile oil, wherein when the composition forms a film on the keratin fibers, it has a water resistance such that ΔL is greater than or equal to 4.5 and/or a sebum...

20060233731 - Use, for the cosmetic treatment of keratin materials, of a film-forming composition comprising an electrophilic monomer and a non-silicone polymer, conferring a soft coating: The present invention relates to the use, for the cosmetic treatment of keratin materials, of a film-forming composition comprising, in a cosmetically acceptable medium, at least one electrophilic monomer and at least one non-silicone polymer such that the film obtained from the composition by drying at ambient temperature and with...

20060233737 - Composition comprising an extract of aphanizomenon flos-aquae, use thereof and preparation of same: The invention relates to a topical composition comprising at least one extract of Aphanizomenon flos-aquae flos-aquae at a concentration of between 0.01 and 10% dry matter in relation to the total weight of the composition. The inventive composition is used to treat the upper layers of the epidermis and/or the...

20060233738 - Composition for promoting production of type 1 collagen and/or elastin: This invention aims to provide a composition that promotes the production of type I collagen and/or elastin in the human skin fibroblast cells, wherein the composition improves the suppleness and elasticity of the skin, is amply effective in preventing and improving wrinkles and sagging, and is also very safe to...

20060233739 - Treatment of mucocutaneous disorders through reversing chronic imflammation and barrier disruption: Topical administration for humans of formulations selected from one or more certain extracts of fruit and/or seeds of berries, date palm, onion and saw palmetto and one or more metallic moieties of metal selected from boron, vanadium and molybdenum. These formulations treat diseases and conditions including visible extrinsic skin aging,...

20060233741 - Alkylated and polymeric macromolecular antioxidants and methods of making and using the same: p

20060233740 - Conjugates of an hgh moiety and a polymer: Conjugates of an hGH moiety and one or more non-peptidic water-soluble polymers are provided. Typically, the non-peptidic water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising such conjugates, methods of making the conjugates, and methods of administering compositions comprising such conjugates to a mammalian subject....

20060233743 - Compositions and methods of therapy: A method of inducing tolerance to an antigen in a patient, the method comprising administering to the patient an agent which raises the effective cAMP concentration in a monocyte cell and GMCSF or a derivative thereof. Preferably, the agent which raises the effective cAMP concentration in a monocyte cell is...

20060233745 - Enclosures housing cell-coated supports for treating tumors: The present invention relates to devices, systems and methods for treating tumors. In particular, the present invention relates to enclosures housing cell-coated supports for promoting regression of tumors, such as cancerous tumors, papillomas, and warts. In preferred embodiments, the present invention provides methods of promoting tumor regression employing enclosures secreting...

20060233744 - In vivo incorporation of unnatural amino acids: The invention provides methods and compositions for in vivo incorporation of unnatural amino acids. Also provided are compositions including proteins with unnatural amino acids....

20060233746 - N-terminally chemically modified protein compositions and methods: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon....

20060233742 - Peptides for the treatment of cancer associated with human papilloma virus (hpv) and other epithelial tumours: This invention is related to the Molecular Pharmacology field and especially to the development of peptides useful for treating epithelial tumors and mainly those associated to oncogenic types of HPVs. The main objective of this invention is to identify peptides whose structure permits to block the Casein Kinase II (CKII)...

20060233747 - Polymer-modified synthetic proteins: The present invention relates to methods and compositions for modifying peptides, polypeptides and proteins with polymers, especially glyco-mimetic polymers, so as to improve their biological activity or pharmacokinetic properties. The invention further provides methods and uses for such polymer-modified peptides, polypeptides and proteins. The invention is particularly suitable for use...

20060233749 - Interleukin-19: The present invention concerns a novel human cytokine. In particular, isolated nucleic acid molecules are provided encoding interleukin-19 (IL-19). IL-19 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The IL-19 polypeptides of the present invention can also be used to raise polyclonal...

20060233750 - Materials and method of modulating the immune response: Methods and materials to modulate the immune response to treat or prevent a disease, including methods of making T helper-antigen presenting cells and methods of using these cells. The invention also relates to methods of making exosome-absorbed dendritic cells and the uses of these cells to modulate the immune response...

20060233748 - Mimetics of interleukin-8 and methods of using them in the prevention, treatment, diagnosis, and ameliorization of symptoms of a disease: The present invention teaches compositions and uses of mimetics of IL-8 in the diagnosis, prevention, treatment, and ameliorization of symptoms of a variety of diseases....

20060233751 - Regulatory t cells suppress autoimmunity: The invention provides methods for producing an autoantigen-specific regulatory T cell enriched composition, and resultant compositions and methods of use....

20060233752 - Method for treating or preventing systemic inflammation in formula-fed infants: The present invention is directed to a novel method for treating or preventing systemic inflammation in a formula-fed infant. The method comprises administering a therapeutically effective amount of LGG to the infant....

20060233759 - Adenoviral vectors having a protein ix deletion: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also...

20060233761 - Alkyl-glycoside enhanced vaccination: Described herein are methods for the noninvasive immunization of a subject that involve alkyl glycosides. Also described herein are compositions, kits, and devices for the noninvasive immunization of a subject....

20060233754 - Compounds promoting delivery of genes: A process is provided for activating gene transfer in a cell by administering a gene transfer activating compound to the cell in conjunction with a gene transfer vector. A kit for activating gene transfer as well as process for identifying a compound that activates gene transfer are described. Use of...

20060233755 - Drug for auditory dysfunction: The present invention provides a pharmaceutical preparation for hearing impairment, which is suitable for gene therapy of hearing impairment, that is, a pharmaceutical preparation for hearing impairment which comprises a virus envelope vector encapsulating a hepatocyte growth factor (HGF) gene or its plasmid as an active ingredient. Particularly, it is...

20060233756 - Recombinant adenoviral vectors and applications thereof: The invention relates to novel recombinant adenoviruses which can be obtained from a replicating adenovirus by deleting all or part of the region of the genome of said replicating adenovirus corresponding to that located in the genome of canine adenovirus type 2 (GenBank J04368) between positions 311 and 499, the...

20060233760 - Splicing variant of tgf-beta2 and uses thereof: An alternatively spliced form of transforming growth factor-beta2 (TGF-β2), herein denoted Δ6-TGF-β2 is disclosed. Δ6-TGF-β2 differs from TGF-β2 in the sequence of the three C-terminal exons. This novel protein is secreted, induced by cytotoxic stress in hematopoietic stem cells, and specifically blocks the enhancing effects of TGF-β2 on adult stem...

20060233758 - Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers: The invention relates to conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein. The peptide may be covalently attached to spacers which may be polyethyleneglycol (PEG), polyglycine, polylysine or any polymer chain suitable for human...

20060233753 - Use of adenoviruses mutated in the va genes for cancer treatment: This invention refers to the use of an adenovirus for cancer treatment, being this adenovirus defective in its virus-associated (VA) RNAs. Said adenovirus has a mutation in the VAI or VAII gene sequence or both. This adenovirus may also have mutations in the sequences controlling expression of the VA RNAs....

20060233757 - Vectors with viral insulators: The invention provides a vector with an isolated viral insulator or variants thereof and uses therefor, e.g., gene therapy or transgenics....

20060233770 - Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine: A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or...

20060233771 - Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands: Methods for promoting dopaminergic neuronal development and producing neural cells having a dopaminergic phenotype are provided. Dopaminergic neural cells may be used for treating individuals having a neurodegenerative disease such as Parkinson's disease. Dopaminergic cells may be implanted into the brain of the individual, and/or dopaminergic neural development may be...

20060233762 - Method for treating or preventing systemic inflammation in formula-fed infants: The present invention is directed to a novel method for treating or preventing systemic inflammation in a formula-fed infant. The method administering to the infant a therapeutically effective amount of LGG in combination with at least one LCPUFA....

20060233774 - Composition for the improvement of liver function, the reduction of serum ethanol level and antioxidant activity enhancement: The present invention is directed to a composition for use in liver function improvement, blood alcohol level reduction and in-vivo antioxidant activity enhancement, comprising Lactobacillus brevis HY7401, Lactobacillus fermentum CS332, Lactobacillus acidophilus CSG, Bifidobacterium longum HY8001, an Alder tree extract, a Selfheal extract, a milk thistle extract, a green bean-rice...

20060233772 - Method for preventing or treating the development of respiratory allergies: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG....

20060233773 - Method for preventing or treating the development of respiratory allergies: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG....

20060233775 - Selection and use of lactic acid bacteria for reducing inflammation in mammals: Strains of lactic acid bacteria selected for their capability of reducing inflammation, such as intestinal bowel disease, a method of selecting such strains, and products containing such strains...

20060233763 - Cartilaginous cell culture medium and the use thereof: A cartilage cell culture medium comprising a basic medium suitable for culturing primary human cells and, said culture medium additionally containing 0.5 to 50.0 ng/ml of EGF, 0.5 to 50.0 ng/ml of FGF, 0.1 to 10.0 ng/ml of PDGF, 0.5 to 50.0 ng/ml of IGF, 1.0 to 100.0 ng/ml of...

20060233768 - Elective collection and banking of autologous peripheral blood stem cells: An elective healthcare insurance model using an individual's own peripheral blood stem cells for the individual's future healthcare uses. An individual can elect to have his or her own stem cells collected, processed and preserved, while he or she is in healthy or “pre-disease” state, for future distribution for his...

20060233769 - Established cell line of microglia: A subcultivatable, established microglia having the following properties. (a) Form: Both or either of a macrophage-like or spherical form in the presence of a granulocyte-macrophage colony stimulation factor and a branched form similar to branched microglia present in the brain in the absence of the factor. (b) Functional characteristics: specific...

20060233767 - Process for producing a tissue transplant construct for reconstructing a human or animal organ: A process for producing a tissue transplant construct for reconstructing a human or animal organ. The process may include the steps of: (a) isolation and two-dimensional cultivation of organ-specific tissue cells; (b) application of the organ-specific tissue cells to a biocompatible, collagen-containing membrane; and, (c) cultivation of the organ-specific tissue...

20060233764 - Skin regeneration system: A cell culture medium and system are provided which eliminate or at least reduce the requirement for exogenous components such as serum and feeder cells. The cell culture medium comprises an IGF and vitronectin or fibronectin and, optionally an IGFBP, and is particularly suitable for propagating keratinocytes for subsequent use...

20060233766 - Treatment of parkinson's disease and related disorders using postpartum derived cells: Cells derived from postpartum tissue such as the umbilical cord and placenta, pharmaceutical compositions comprising such cells, and methods for using such cells and pharmaceutical compositions to treat patients having a neurodegenerative condition of the substantia nigra or striatum, such as Parkinson's disease, are provided....

20060233765 - Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells: Cells derived from postpartum tissue such as the umbilical cord and placenta, and methods for their use to regenerate, repair, and improve neural tissue, and to improve behavior and neurological function in stroke patients are disclosed....

20060233776 - C1-inh as a drug for treating viruses pathogenic to humans: The C1 esterase inhibitor (C1-INH) from human plasma is a sialic-acid-containing glycoprotein which can bind other glycoproteins and glycolipids which may be components or even membrane components of microoganisms of viral and bacterial origin. In accordance with the invention, this binding can inhibit the penetration of certain viruses into target...

20060233779 - Ring finger family proteins and uses related thereto: The application provides, among other things, specificity domains, and methods for identifying and using specificity domains....

20060233778 - Stability for injection solutions: A primary package containing a low molecular weight peptide-based thrombin inhibitors which package is sealed with a rubber stopper or plunger containing bromobutyl rubber....

20060233777 - Use of bacteriocin for the amelioration of digestive functionality: The subject of the present invention is the use of bacteriocins and/or their producer strains for the amelioration of digestive functionality and for the amelioration of gastrointestinal tract conditions in monogastric organism species....

20060233780 - Method for treating oncological diseases: The invention relates to medicine and veterinary science and can be used for treating mainly solid tumors. The inventive method for treating oncological diseases consisting in injecting a blood extracellular DNA destroying agent into a systemic blood circulation. Said blood extracellular DNA destroying agent can be embodied in the form...

20060233781 - Antimicrobial composition for local use on mucosal membranes and skin: The invention relates to an antimicrobial composition for local use on mucosal membranes and skin. The antimicrobial composition comprises a system of lysozyme and glycosylated immunoglobulins. The glycosylated immunoglobulins have affinity towards gram negative and gram positive bacteria and viruses. Moreover, the invention concerns the method of preparation of said...

20060233782 - Proteoglycan degrading mutants for the treatment of cns: The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease....

20060233784 - Adamts13 genes and proteins and variants, and uses thereof: The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments,...

20060233783 - Topical composition in the form of a gel for treating skin burns: The present invention relates to novel topical compositions for treating burns, grazes, erythema, eczema, herpes infection, evulsion, sores and any skin damage leading to sloughing, including at least three components, namely a first barrier gel, a second barrier gel and an active principle having proteolytic activity. The novel compositions have...

20060233786 - Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation: Formulations for neutralizing the anticoagulant action of a human tissue factor inhibitor, comprising a blood coagulation factor complex product or an activated blood coagulation factor VII product as an active ingredient; and formulations for neutralizing the blood coagulation-promoting action of an activated blood coagulation factor VII product, comprising a human...

20060233785 - Immunointeractive molecules and uses thereof: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having latex allergy and genetic sequences encoding the same. These molecules are preferentially immunointeractive with T cells in subjects having a Hev b 6 allergy. The present invention also...

20060233787 - Human cd3-specific antibody with immunosuppressive properties: Described are mono- and multivalent scFv-antibodies comprising the binding sites specific for human T cell marker CD3. These antibodies are strongly immunosuppressive and do not cause a significant release of cytokines. Furthermore, polynucleotides encoding said antibodies are described as well as vectors comprising said polynucleotides, host cells transformed therewith and...

20060233788 - Anti-ghrelin antibodies: Monoclonal antibodies, including humanized and chimeric antibodies, that bind acylated and unacylated human ghrelin are provided. Such monoclonal antibodies can be full-length, or an antigen-binding portion thereof, and are useful for neutralizing ghrelin activity, e.g., in a human subject suffering from a disorder in which ghrelin activity is detrimental....

20060233789 - Process for producing antigenic substance: An object of the present invention is to provide a means for producing an antigenic component with the retained native antigenicity using a cell-free protein synthesis. In particular, it is an object to provide a means for producing an antigenic component without depending on codon usage, like expressing an antigenic...

20060233791 - Anti-cd19 antibodies and uses in oncology: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to...

20060233790 - Immunoglobulin/hydrophilic peptide complexes: The present invention provides an immunoglobulin preparation comprising an immunoglobulin-hydrophilic peptide complex in which an immunoglobulin and a hydrophilic peptide are linked optionally via a divalent group, and a pharmacologically acceptable carrier. The immunoglobulin preparation has cell permeability, or in other words, it can penetrate through a cell membrane and...

20060233792 - Train-r: a cysteine rich member of the tnf-receptor family: Novel receptor in the TNF family: TRAIN-receptor....

20060233794 - Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders: Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical...

20060233796 - Method of modulating memory effector t-cells and compositions: This invention relates to methods of using inhibitors of the CD2/LFA-3 interaction in treating conditions characterized by the presence of activated T cells in mammals, including humans. Such conditions include inflammatory bowel diseases, psoriatic arthritis, rheumatoid arthritis, and multiple sclerosis....

20060233798 - Methods for inhibiting hiv-1 infection: This invention provides a method of reducing an HIV infected subject's HIV-1 viral load which comprises administering to the subject an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor and (b) inhibits fusion of HIV-1 to a CD4+CCR5+ cell, so as to...

20060233795 - Methods for selectively modulating a th2-type response within a population of activated cd4+ t cells: Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells are provided. The methods of the invention involve contacting the CD4+ T cells with an agent which modulates a B7-2-induced signal in the CD4+ T cells, such that the Th2-type response is modulated. Methods for...

20060233797 - Treatment of inflammatory bowel disease (ibd): The present invention concerns treatment of IBD, especially ulcerative colitis (UC), with an antibody that binds to CD20....

20060233793 - Use of anti-cd100 antibodies: The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as...

20060233800 - Biological products: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the...

20060233801 - Compositions and methods for increasing bone mineralization: A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules. In particular, compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate...

20060233804 - Igf antagonist peptides: Peptides are provided that antagonize the interaction of IGF-1 with its binding proteins, insulin receptor, and IGF receptor. These IGF antagonist peptides are useful in treating disorders involving IGF-1 as a causative agent, such as, for example, various cancers....

20060233802 - Tumour necrosis factor binding ligands: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of...

20060233803 - Use of a33 antigens and jam-it: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer....

20060233799 - Use of il-18 inhibitors for treatment and/or prevention of peripheral vascular diseases: The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation....

20060233805 - Antigen uptake receptor for candida albicans on dendritic cells: Dendritic cells (DC) that express the type II C-type lectin DC-SIGN (CD209) are located in the submucosa of tissues, where they mediate HIV-1 entry. Interestingly, the pathogen Candidaalbicans, the major cause of hospital-acquired fungal infections, is found at similar sites. Here it is demonstrated that DC-SIGN is able to bind...

20060233811 - Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents: The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods...

20060233809 - Method for treating prostate conditions: The invention provides a method for inhibiting the aberrant growth of cells in a prostate tissue in an individual comprising administering to the individual an amount of an inhibitor of the Breast Cancer Resistance Protein (BCRP/ABCG2), where the amount of the BCRP inhibitor is effective to inhibit the growth of...

20060233810 - Methods and compositions for treating or preventing cancer: This invention relates to compositions and methods useful for treating various cancers. Therapeutic combinations and methods of use thereof are also covered in the present application....

20060233807 - Novel therapies and methods of screening for therapeutic compounds: A method for killing cells, said method comprising introducing into the nucleus of the cell, a moiety (other than HAMLET) which inhibits histone activity. This method will be useful for example in the treatment of cancer for antibacterial activity. Histones can be used as a basis of screening methods to...

20060233808 - Peptabody for cancer treatment: The present invention relates to an isolated and recombinant fusion peptabody, which binds to a member of the epidermal growth factor receptor useful in inhibiting the growth of certain tumor cells. Also disclosed are, nucleic acids encoding said isolated and recombinant fusion peptabody, kits and pharmaceutical compositions comprising said isolated...

20060233806 - Removal promoters and inhibitor for apoptosis cells in vivo: The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk...

20060233812 - Focussed antibody technology: The present invention concerns methods for identifying candidate sequences for antibody specific against an antigen produced by a micro-organism during an infection or against a vaccine, methods of manufacture of medicaments, and methods of treatment of patients using same. Also provided is a method for determining the efficacy of a...

20060233813 - Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith: The present invention relates to molecules that are capable of killing cells. The molecules comprise a targeting agent and a channel-forming moiety. The molecules may be polypeptides. The present invention also relates to polynucleotide sequences encoding the polypeptides of the invention. In a preferred embodiment, the channel-forming moiety comprises a...

20060233814 - Elimination of heterogeneous or mixed cell population in tumors: Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates...

20060233815 - Agents for protection from neointimal formation in grafts comprising an nfkappab decoy: The present invention provides methods for using NFκB decoys to regulate (suppress) transcription activated by NFκB, and to suppress neointimal formation in grafts. Furthermore, the present invention relates to agents for protection from intimal thickening in vascular grafts that comprise NFκB decoys....

20060233816 - Use of plant oil-bodies in vaccine delivery systems: The present invention relates to the use of oil bodies as a vaccine adjuvant and delivery system for administration of vaccines by parenteral, mucosal (oral, nasal, pulmonary) and transdermal routes. In addition, the present invention relates to methods of eliciting an immune response in an animal by administering oil body-antigen...

20060233819 - Inhibition of t cell activation by butyrophilin 4 or b7-l1: The invention provides methods for modulating an immune response comprising contacting an immune cell with an agent that modulates BTF4 or B7-L1 mediated signaling. BTF4 or B7-L1 mediated signaling may either be increased, to thereby downregulate the immune response, or alternatively may be decreased, to upregulate the immune response. Modulation...

20060233818 - Organic compounds: Dendritic cell (DC) genes and polypeptides and their function in the identification of compounds which are (ant)agonists; and (ant)agonists to DC polypeptides....

20060233817 - Peptide-based immunization therapy for treatment of atherosclerosis: The present invention relates to a fragment of apolipoprotein B, for immunization for prophylactic or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, in particular myocardial infarction or stroke, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing ischemic...

20060233821 - Compositions and methods for the inhibition of membrane fusion by paramyxoviruses: Fusion of the membrane of enveloped viruses with the plasma membrane of a receptive host cell is a prerequisite for viral entry and infection and an essential step in the life cycle of all enveloped viruses, such as paramyxoviruses. The instant invention is directed to providing polypeptides which are a...

20060233820 - Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus: The invention relates to an immunogenic or vaccine composition inducing an immune response towards the HPV-16 Papillomavirus native E7 protein, without simultaneously inducing an immunosuppression, said composition comprising, as the active ingredient, a non immunosuppressive mutated E7 protein, comprising the amino acid sequence consisting, from the N-terminal end to the...

20060233822 - Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof: The present invention relates to monoclonal antibody specifically binding to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its conserved variants or its active fragments, or other monoclonal antibodies against ORF2 which can cross react with said...

20060233825 - C. perfringens alpha toxoid vaccine: The present invention describes vaccines that comprise C. perfringens Type alpha toxoids, antigenic fragments thereof, inactivated antigenic fragments of C. perfringens Type alpha toxins, or any combination thereof. The present invention further describes methods of using with these vaccines to protect animals against clostridial diseases. The present invention also describes...

20060233823 - Nucleic acids and proteins of the mycoplasma hyopneumoniae mhp3 gene and uses thereof: The present invention relates to mhp3 nucleic acids and proteins encoded by the foregoing. The present invention further relates to novel apoprotein antigens encoded by mhp3 for use in vaccines to prevent and treat diseases caused by infection with Mycoplasma hyopneumoniae. The invention further relates to methods for the recombinant...

20060233824 - Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides....

20060233826 - Porin b (porb) as a therapeutic target for prevention and treatment of infection by chlamydia: The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which...

20060233827 - 85kda neisserial antigen: An 85kDa antigen from Neisseria meningitidis and Neisseria gonorrhoeae has been cloned, sequenced and expressed. The antigen is common to diverse strains, serogroups and serotypes of N. meningitidis, and also to N. gonorrhoeae, N. polysaccharia and N. lactamica. The protein sequences of N. meningitidis (serogroups A and B) and N....

20060233828 - Dietary supplement including he shou wu, parasitic loranthus and green tea to promote weight loss: A novel dietary supplement composition that serves to inhibit FAS for the purpose of controlling body weight and body fat levels. Administration of the composition, particularly to individuals with impaired glucose tolerance, may have the effect of restoring optimal glucose functioning, therefore lessening the likelihood of adipose storage and leading...

20060233829 - Regulated attenuation of live vaccines to enhance cross-protective immunogenicity: A live attenuated derivative of a pathogenic bacterium intended for use as a vaccine...

20060233831 - Novel vaccine formulations: The present invention relates to oil-in-water emulsions, their use as adjuvants, and pharmaceutical, immunologic, or vaccine compositions that may comprise the same. In one embodiment, the oil-in-water (O/W) emulsion may comprise an aqueous solution containing an immunogen, a mineral oil, a non-ionic lipophilic ethoxylated fatty alcohol and a non-ionic hydrophilic...

20060233830 - Vaccines: Processes for the production of a stabilised vaccine composition of labile immunogens, wherein a fluid comprising one or more immunogens is sprayed into a reactor containing fluidised particles of a pharmaceutically acceptable water soluble material at a temperature of about 25° C. to about 50° C., such that the immunogen...

20060233832 - Composition for the prophylaxis and treatment of hbv infections and hbv-mediated diseases: The present invention is a composition that comprises at least two hepatitis B virus surface antigens (HBsAgs), fragments thereof and/or nucleic acids encoding them, the HBsAgs differing in HBV genotype in the S region and/or pre-S1 region and the composition containing no HBV core antigen (HBcAg) or nucleic acid encoding...

20060233833 - Novel uses of parapoxvirus preparations: The present invention related to use of Parapoxvirus preparations for the treatment of conditions related to infections with strictly intracellular bacteria...

20060233834 - Production of poxviruses with adherent or non adherent avian cell lines: The present invention relates to a method for replicating pox viruses such as vaccinia virus comprising the steps of inoculating avian embryonic stem cells with viral particles and culturing said cells in a basal medium until cells lysis occurs and newly produced viral particles are released in said medium....

20060233835 - Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector: The present invention comprises methods for enhancing the immunogenicity of a bacterial vaccine vector and an antigen by passaging the bacterial vaccine vector through an animal....

20060233836 - Methods for identifying inhibitors of botulinum neurotoxins: A system and method for identifying a botulinum neurotoxin inhibitor employing a botulinum neurotoxin substrate complex having a peptide substrate, preferably SNAP-25, a reporter domain on one side of said peptide substrate and an immobilization domain on the opposite side of said peptide substrate. The botulinum neurotoxin inhibitor is identified...

20060233837 - Vibrio cholerae vaccine candidates, the methods of their constructing and medicinal preparations derived thereof: A single oral administration dose medicinal preparation is derived from Vibrio cholerae vaccine strains which have a disrupted hemagglutinin protease gene and which are tagged with celA coding functions from Clostridium thermocellum are described. The strains are freeze-dried and derived from non toxigenic parented strains. The medicinal preparation includes lyopectrants....

20060233838 - Method for the purification, recovery, and sporulation of cysts and oocysts: A vaccine for in ovo vaccination against avian coccidiosis produced by a method including obtaining the coccidial oocysts from a fecal suspension, homogenizing the fecal suspension, separating the oocysts from the fecal debris by either salt flotation using sodium sulfate or gas flotation using air, sporulating the oocysts using hydrogen...

20060233839 - Novel compounds: The present invention provides a novel treatment for allergy comprising the provision of a recombinant Der p 1/ProDer p 1/PreProDer p 1 allergen derivative, ProDer p 3 or a recombinant ProDer p 3/Der p 3/PreProDer p 3 allergen derivative with hypoallergenic activity. Pharmaceutical compositions comprising said mutant allergens which stimulate...

20060233840 - Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby: The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby....

20060233841 - Implantable gel compositions and method of manufacture: Methods and compositions for reducing the burst of beneficial agent from implantable systems is described. Such systems utilize compressed particulates of a beneficial agent, optionally mixed with a dissolution rate modulator or an agent exhibiting a characteristic of low solubility in water, such as a mixture of stearic acid and...

20060233844 - Method for the delivery of a biologically active agent: A method of manufacturing a stable nanosuspension for delivery of a biologically active agent into the bloodstream of a subject is disclosed. A microfluidizable mixture is initially formed and processed via a microfluidization process to form the stable nanosuspension, which may be administered via the buccal mucosa or other suitable...

20060233842 - Microemulsion composition for oral administration of biphenyldimethyldicarboxylate: A microemulsion composition comprising biphenyldimethyldicarboxylate (DDB), a co-surfactant, a surfactant and an oil provides an improved stability and a high in vivo bioavailability of biphenyldimethyldicarboxylate when orally administered....

20060233843 - Treatment of psychosis with a muscarinic m1 receptor ectopic activator: A muscarinic M1 receptor ectopic activator, such as a muscarinic M1 receptor allosteric potentiator or a muscarinic M1 receptor ectopic agonist is useful, alone or in combination with other antipsychotic agents, for treating or preventing psychosis, such as a schizophrenic disorder or psychosis in Alzheimer's disease or bipolar disorder, for...

20060233847 - Apparatus and method for manufacture of cosmetic applicator: A method of manufacturing a plurality of cosmetic applicators including providing an electrostatic control means for dissipating electrostatic charge or localising electrostatic charge wherein the powder at least in part is retained on the cosmetic applicator surface with the assistance of electrostatic attraction between said surface and said cosmetics preparation....

20060233845 - Micro/nanoparticle obtained from lipid-containing marine organisms for use in pharmaceutics and cosmetics: The invention relates to pharmaceutically or cosmetically active agents, which are obtained by converting biomasses consisting of lipid-containing marine organisms into microparticles and nanoparticles and which preferably have an average diameter of 10 nm 10 μm. Possible fields of application of these agents include the field of medicine, the production...

20060233846 - Microdispersion and method of producing same: The invention describes homogeneous microdispersions comprising at least one hydrogenated or partially hydrogenated membrane lipid with or without enzyme hydrolysis, dispersed in substantially non aqueous, non volatile hydrophilic medium with boiling point above 40° C. More preferably the compositions comprise a mixture of hydrogenated monoacyl and hydrogenated diacyl-lipids and at...

20060233848 - Composition for luring and controlling arthropods comprising synthetic silicic acid and protein autolysate: The invention relates to a composition comprising protein autolysates derived from yeasts and synthetic silicic acids, and also, optionally, active compounds directed against animal pests, for luring and controlling animal pests, which composition can be used in agriculture, in horticulture, in forestry, in animal husbandry, in animal breeding, in the...

20060233853 - Bone growth compositions and methods: The present invention provides an improved technique for spinal fusion involving the administration of an HMG-CoA reductase inhibitor to a fusion. The HMG-CoA reductase inhibitor is preferably delivered to the site by a carrier. More preferably, the HMG-CoA reductase inhibitor is delivered to the site by a non-compressible delivery vehicle....

20060233849 - Composite bone graft material: A bone graft material comprising about 50-90% quickly bioresorbable porogen particles and about 10-50% of a calcium phosphate compound or salt matrix material. A bioactive substance may be included in the matrix material, the porogen particles, or both. Commercial packages containing the bone graft materials and methods for repairing bone...

20060233851 - Composite bone graft material: A bone graft material comprising about 50-90% quickly bioresorbable porogen particles and about 10-50% of a calcium matrix material. A bioactive substance can be included in the matrix material, the porogen particles, or both. Commercial packages containing the bone graft materials and methods for repairing bone therewith are also claimed....

20060233850 - Hydrogel bioscaffoldings and biomedical device coatings: Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other...

20060233854 - Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same: The present invention relates to biodegradable scaffolds composed of a naturally-occurring protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides PEGylated-fibrinogen scaffold and methods of generating and using same for treating disorders requiring tissue regeneration....

20060233855 - Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same: A method of treating a disorder characterized by tissue damage is provided. The method comprising providing to a subject in need-thereof a composition which comprises a synthetic polymer attached to denatured fibrinogen or a therapeutic portion of the fibrinogen, the composition being formulated for releasing the therapeutic portion of the...

20060233852 - Prosthetic for tissue reinforcement: A process for the manufacture of a prosthetic sheet with improved tissue healing characteristics useful in reinforcing tissue defects is disclosed. Generally the prosthetic may be comprised of any material that does not promote fibrosis and inflammation. In particular, the prosthetic may be comprised of non-absorbable hydrogel reinforced with fiber,...

20060233856 - Method for hand rejuvenation: The present invention provides a method of rejuvenating human skin by implanting a sheet formed of a pliable biocompatible material beneath the skin surface so as to generate a substantially smooth layer that augments a thickness of the skin portion. The biocompatible sheet has preferably a thickness sufficient for substantially...

20060233857 - Degradable elastomeric network: One aspect of the invention provides a degradable/biocompatible elastomer. The elastomer comprises a degradable cross-linked network of a hydrophobic, hydrolysable amorphous star polymer and a hydrophilic, biocompatible polymer. The network may be crosslinked thermally or by irradiation. In a preferred embodiment, the elastomer is used for a drug delivery system,...

20060233860 - Alpha-2 agonist polymeric drug delivery systems: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix,...

20060233859 - Methods for treating retinopathy with extended therapeutic effect: Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy....

20060233858 - Systems and methods providing targeted intraocular drug delivery: Drug delivery systems suitable for administration into the interior of an eye of a person or animal are described. The present systems include a drug delivery element that provides directional delivery of one or more drugs to a desired target site in the eye and remain invisible to the individual...

20060233861 - Modulation of atp production or content in the hypothalamus: A method for the identification of agents for use in the treatment of metabolic diseases, disorders or conditions, for example obesity and diabetes, or for causing weight loss without substantial adverse health effects, in an animal in need of such treatment, comprises the step of identifying an agent that modulates...

20060233863 - Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy: Described herein are various lipid mixtures, more particularly special mixtures of fatty acids esters, which may be phytosterol esters and/or glyceride esters. Said mixtures are evaluated in the context of their ability to, upon consumption, affect the levels of circulating LDL and HDL particles, and their therapeutic effect on conditions...

20060233862 - Process for the preparation of a fat composition containing sterol esters a product obtained by said process and the use thereof: A method for preparing a fat composition by reacting a sterol raw material with a triglyceride raw material to create the fat composition....

20060233864 - Methods for improving the nutritional quality of residues of the fuel, beverage alcohol, food and feed industries: A method is provided for improving the nutritional quality of a fibrous by-product or residue of a food manufacturing process, wherein the fibrous by-product or residue is inoculated with at least one filamentous fungus, and the fibrous by-product or residue is fermented thereby to decrease dry matter content, increase protein...

20060233867 - Article of clothing for treating a tumor or the like: An article of clothing is provided for selectively destroying dividing cells in living tissue formed of dividing cells and non-dividing cells. The dividing cells contain polarizable intracellular members and during late anaphase or telophase, the dividing cells are connected to one another by a cleavage furrow. The article of clothing...

20060233868 - Disinfectant delivery system and method of providing alcohol free disinfection: A disinfectant delivery system and method of providing alcohol-free disinfection to a body to be disinfected, as well as a method of infection reduction by preparation of a patient before an invasive procedure. A blended cloth comprising first fibers and second fibers is provided with the first fibers generally being...

20060233869 - Hemostatic devices and methods of making same: The present invention includes compositions suitable for use in a hemostatic device and hemostatic devices utilizing such compositions, as well as methods of making the compositions and the medical devices utilizing such compositions where the compositions contain biocompatible, oxidized cellulose particles having an average designated nominal particle size of about...

20060233866 - Products comprising an applicator and a wax dispersion: This invention concerns products for cleansing and other applications, which products comprise an applicator such as a puff (pouf), pad, sponge, foam, mitt, glove, swab, cotton ball or bar, to which a wax dispersion has been applied. The invention further concerns the manufacture and use of such products....

20060233865 - Wax composition and method for production thereof: A process of producing a wax composition mainly comprising a wax, including the step of mixing the wax and a component to be mixed with the wax by applying an external force at a temperature lower than the melting completion temperature of the wax....

20060233870 - Compositions and methods for drug delivery: A dermal composition for administration of an amphetamine drug comprising a blend of two or more acrylic-based polymers having differing functionalities so as to modulate the drug solubility in the polymer matrix and the delivery rate of the drug, and methods therefor....

20060233871 - Transdermal delivery system for dried particulate or lyophilized medications: The present invention provides a system for transdermal delivery of dried or lyophilized pharmaceutical compositions and methods using thereof. The system comprises an apparatus for facilitating transdermal delivery of an agent that generates hydrophilic micro-channels, and a patch comprising a therapeutically active agent. The present invention is useful for transdermal...

20060233873 - Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same: The present invention concerns a dispersion of crystals or granules of active substance in a lipophilic vehicle, said crystals or granules being coated by a coating for taste masking purposes. The invention also it concerns unit dosage forms and preferentially chewable or fast dissolving soft gelatin capsules filled with said...

20060233872 - Pharmaceutical product which is used to reduced or stop moderate or severe snoring: The invention relates to the novel use of a pharmaceutical product which combines domperidone and pseudoephedrine sulphate substances and which can be used to reduce or stop moderate or severe snoring....

20060233874 - Seamless capsule: A seamless capsule including a filler material and a shell which encapsulates the filler. The shell comprises (a) a shell material and (b) a crystallization agent which is one or two or more selected from a group consisting of sorbitol, mannitol, xylitol, erythritol, paratinitt, lactitol, maltitol, trehalose, and saccharose. The...

20060233876 - Compositions and methods for reducing cardiovascular morbidity and/or mortality: The present invention is related to a method for reducing cardiovascular morbidity and/or mortality comprising administering a combination comprising an ACE inhibitor and a CCB, specifically benazapril and amlodipine besylate....

20060233875 - Taste masked sumatriptan tablets and processes for their preparation: The technical field of the present invention relates to uncoated, taste masked sumatriptan tablets for oral administration and processes for their preparation. It also relates to wax polished sumatriptan tablets and processes for their preparation....

20060233877 - Betaine compositions: The invention refers to the pharmaceutical combination including at least: a first compound selected among the group consisting of acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of Formula (CH3)3N+(CH2)nCOO− with n an integer from 1...

20060233878 - Extended release formulation of beta-lactam antibiotics: A pharmaceutical composition for controlled drug delivery comprising a β-lactam antibiotic or its pharmaceutically acceptable hydrates, salts or esters, and one or more carbomers. The above β-lactam antibiotics formulation avoids the limitations of known β-lactam controlled release form which are found to be either complex and/or cost-extensive to obtain requiring...

20060233880 - Controlled release dosage forms: A zero-order release pharmaceutical dosage form for oral administration to a patient comprising a core tablet sheathed in an annular body of compressed powder or granular material is provided. A preferred embodiment of the zero-order release pharmaceutical dosage form is a solid pharmaceutical dosage form which reduces contact of the...

20060233879 - Controlled released dosage forms: A zero-order release pharmaceutical dosage form for oral administration to a patient comprising a core tablet sheathed in an annular body of compressed powder or granular material is provided. A preferred embodiment of the zero-order release pharmaceutical dosage form is a solid pharmaceutical dosage form which reduces contact of the...

20060233881 - Modified release dosage form: The present invention relates to a medicinal dosage form having a first core, a second core, and a shell that surrounds a first portion of each core and a fill material that covers a second portion of at least one core, wherein the fill material that is provided over at...

20060233882 - Osmotic dosage form: The present invention is directed to a modified release dosage form for delivering at least one pharmaceutically active ingredient. The dosage form has a first immediate release core for an active ingredient and an osmotic core or osmotic chamber containing at least one pharmaceutically active ingredient that can be the...

20060233883 - Intravenous nanoparticles for targeting drug delivery and sustained drug release: Provided are poly(lactic-co-glycolic acid) (PLGA) and poly(lactic acid) (PLA) nanoparticles that encapsulate a low molecular weight and water-soluble drug and can deliver the drug to target legion sites where the particles gradually release the drug over a prolonged period of time. The nanoparticles are prepared by allowing the low-molecular, water-soluble...

20060233884 - Sexual hygienic composition: The invention is a sexual hygienic preparation comprising extract prepared from the milk of at least one equid animal. The preparation may contain medically/therapeutically acceptable additive(s) in specified cases. The preparation is formulated preferably as a feminine cleansing gel, feminine cleansing shampoo, feminine cleansing soap, vaginal suppository, vaginal pill, vaginal...

20060233885 - Analgesic agent for newborn or fetal subjects: In a first aspect, the present invention relates to the use of xenon in the preparation of a medicament for providing analgesia in a newborn subject and/or a fetal subject. In a second aspect, the invention relates to a method of providing analgesia in a newborn subject, the method comprising...

20060233886 - Antimicrobial composition and method for making same: Anti-microbial Formulations and methods of their use and production are disclosed. The Formulations of the present invention are effective as broad spectrum anti-bacterial agents with efficacy against both Gram-negative and Gram-positive bacteria, as anti-viral agents with efficacy against both enveloped and non-enveloped viruses, anti fungal agents and anti spore forming...

20060233887 - Bioactive material for use in stimulating vascularization: The present invention relates to a bioactive material, particularly one which comprises SiO2 and CaO and optionally Na2O and/or P2O5, for use in stimulating vascularisation and pharmaceutical compositions, wound dressings, tissue constructs and delivery systems which include such a bioactive material....

20060233888 - Silver coatings and methods of manufacture: A silver composition comprising silver sulfate and a method of coating the composition on a substrate is disclosed....

20060233889 - Silver coatings and methods of manufacture: A silver composition comprising silver sulfate and a method of coating the composition on a substrate is disclosed....

20060233890 - Method for treating a mammal by administration of a compound having the ability to release co: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached...

20060233891 - Methods and devices for the in situ dissolution of renal calculi: Methods and devices for at least reducing the mass of, if not dissolving, renal calculi in situ are provided. In the subject methods, a renal calculus is contacted, e.g. flushed, with an acidic dissolution solution in situ, where the acidic dissolution solution is a solution of a strong, inorganic acid,...

20060233892 - Topiramate compositions for treatment of headache: A composition containing from about 10 to about 50 mg of topiramate in combination with one or more of parthenolide, magnesium and riboflavin is effective for treating headaches, and particularly migraine headaches, while reducing or eliminating the side effects experienced by users of prior higher dose topiramate compositions....

20060233893 - Aqueous solutions for the reduction of fatty tissue: The present invention relates to isotonic or hypotonic aqueous solutions which are hyperkalaemic or which contain tiratricol and/or phosphatidylcholine, and to their use in the reduction of fatty tissue....

20060233894 - Anti-inflammatory humate compositions and methods of use thereof: The disclosure relates to an anti-inflammatory composition containing humate, such as insoluble, granular, other insoluble, or soluble humate, particularly Menefee Humate®. The disclosure also includes other anti-inflammatory compositions containing humate and at least one additional anti-inflammatory agent such as indomethacin or another nonsteroidal anti-inflammatory drug. The disclosure includes a method...

20060233895 - Herbal remedy for treating lyme disease: The present invention is directed to a composition for the treatment of Lyme disease, comprising: Uncaria tomentosa (Cat's Claw); Pau d'arco; Scutellaria baicalensis (Baikal Scullcap); Artemisinin; and Sambucus nigra (Elderberry)....

20060233896 - Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same: The body of a herbaceous plant, Cistanche tubulosa (Schenk.) Wight, is used to make a medicinal preparation containing phenylethanoid glycosides and comprising 10-70% of echinacoside by weigh of the preparation and 1-40% of acteoside by weight of the preparation. The medicinal preparation is used as an active ingredient of medicinal...

20060233897 - Agent for preventing, improving or treating hypertension: (B) a component selected from the group consisting of central nervous system stimulating components, food fibers, extracts of perennial evergreen leaves of the genus Camellia, Theaceae, or Eucommia ulmoides Oliver, Eucommiae, organic acids having a molecular weight of 60 to 300 (excluding citric acid) and pharmaceutically acceptable salts thereof, and...

20060233898 - Ingestible compositions containing extracts: The present invention relates to ingestible compositions containing cotinus coggygria extract and/or malva sylvestris extract and the use thereof in enhancing the elasticity or structural integrity of skin, urogenital tissue, blood vessel walls, or mucosal tissue and/or reducing the levels of triglycerides or uric acid....

20060233899 - Treatment of human multiple myeloma by curcumin: All multiple myeloma cell lines examined showed constitutively active IκB kinase (IKK), IκBα phosphorylation and constitutively active NF-κB. Curcumin, a chemopreventive agent, suppressed constitutive IκBα phosphorylation through inhibition of IKK activity and downregulated NF-κB. Curcumin also downregulated expression of NF-κB-regulated gene products such as IκBα, Bcl-2, Bcl-xL, cyclin D1 and...

20060233900 - Preparation for reducing the appetite, producing a satiated feeling and/or for weight loss in children: The present invention relates to a preparation for children at the age of up to 17 years for long-lasting appetite reduction, satiation and/or weight reduction, comprising carob bean flour or a mixture of these substances and at least one fatty acid and/or its derivatives....

20060233901 - Oils of capsaicinoids and methods of making and using the same: Oils of capsaicinoids and methods of making and using them are described. In some variations, the oils of capsaicinoids comprise at least 40% w/w capsaicinoid and a solvent capable of solubilizing the capsaicinoid, wherein the oil of capsaicinoid is substantially free of capsaicinoid crystals or capsaicinoid precipitates. In other variations,...

20060233902 - Compositions and foods for improving lipid metabolism: It is intended to provide compositions and foods for use in the treatment, prophylaxis, or amelioration of diseases or symptoms which can be treated, prevented or ameliorated by activating PPAR, in particular, insulin resistant diabetes and hyperlipidemia. Namely, medicinal compositions usable in treating, preventing or improving diseases or symptoms which...

20060228298 - Imaging and selective retention of phospholipid ether analogs: The present invention generally relates to imaging and selective retention of phospholipid ether analogs in various neoplastic tissues. Specifically, the present invention relates to imaging and methods for selective retention of analogs, for example, NM404, in cancers such as Colorectal Cancer....

20060228296 - Method of screening groups of radioactive molecules and applications thereof: The invention relates to an amplification-free method of screening groups of radioactive molecules, the products from the molecule groups obtained and the application thereof in order to identify molecules that are capable of binding selectively to a tissue or a particular organ. The inventive method can be used for the...

20060228297 - Thorium-227 for use in radiotherapy of soft tissue disease: The invention provides a method for the treatment of soft tissue disease in a mammalian subject (preferably a human or canine subject), said method comprising administering to said subject a therapeutically effective quantity of a soft tissue targeting complex of thorium-227 and a complexing agent, wherein said quantity is such...

20060228299 - Constructs binding to phosphatidylserine and their use in disease treatment: Disclosed are new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof. The new constructs effectively bind phosphatidylserine targets in disease and enhance their destruction, and can also specifically deliver attached imaging or therapeutic agents to the disease site. Also disclosed are...

20060228300 - Stably tethered structures of defined compositions with multiple functions or binding specificities: The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an...

20060228301 - Methods and compositions for determining targeted drug sensitivity and resistance in a cancer subject: Diagnostic and therapeutic methods of cancer treatment and prevention using metabolic profiling compounds that contain [1,2-13C2]-D-glucose, and kits for using such metabolic profiling compounds....

20060228302 - Directed complementation: A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary...

20060228303 - Method of screening for genes that influence pathological conditions or survival of animals infected with pathogen: Efficient screening of genes that influence pathological conditions or survival of animals infected with pathogen is enabled by the use of a full-length cDNA library as DNAs for immunizing animals in place of a genomic DNA library, used in the conventional ELI method....

20060228304 - Liquid embolisate: The invention relates to a liquid embolizate, especially for the occlusion of vascular malformations. Said liquid embolizate is made of: a) 20-80% v/v of an occlusion mixture which contains a zein emulsion in aqueous ethanol, b) 10-40% v/v of a radiopaque contrast medium in liquid form and c) 10-40% v/v...

20060228306 - Combination antihistamine and steroid medication: The invention provides a topical pharmaceutical composition for application to the nasal or ocular mucosa which comprises (1) a pharmaceutical excipient suitable for topical administration, (2) an antihistamine drug and (3) a mast cell stabilizer, a non-steroidal anti-inflammatory drug, a phosphodiesterase inhibitor, an anti-IgE agent, heparin, a topical steroid or...

20060228305 - Pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action: The present invention relates to novel pharmaceutical compositions based on anticholinergics and TNF-alpha-antagonists, processes for preparing them and their use in the treatment of respiratory diseases....

20060228307 - Structures and methods for delivering topical compositions: Structures and methods for delivering topical compositions are disclosed that fully integrate the topical composition with a carrier. One example adds a liquid topical composition, such as a dental bleach, to a liquid polymer carrier, mixes the two, and then solidifies the mixture. The solidified mixture is a delivery device...

20060228308 - Oral health care drink and method for reducing malodors: An oral care composition and method of using are provided for treating and preventing malodors or disease conditions of the oral cavity in warm-blooded animals, including humans. When applying an oral care effective amount of the oral care composition of the present invention to the mucosal tissue of the oral...

20060228312 - Delivery system for film-forming polymer: A film-forming composition formed by solubilizing higher concentrations of polyanhydride resins using a mixture of a fatty acid triglyceride derivative and a diester of 2-Octanol and Adipic Acid. In one embodiment, a composition in accordance with the invention comprises between about 1% and 55% by weight of Furandione (2,5)-Polymer with...

20060228311 - Photoabsorbing, highly conjugated compounds of cyanoacrylic esters, sunscreen compositions and methods of use: Novel derivatives of α-cyano-β-naphthyl acrylates, sunscreen compositions including one or more α-cyano-β-naphthyl acrylate derivatives are described herein. Also disclosed are methods for stabilizing a sunscreen composition and methods of filtering out ultra-violet light from a substrate by the addition of one or more of the foregoing α-cyano-β-naphthyl acrylate derivatives....

20060228309 - Skin lightening composition comprising an extract of plants from the families of symplocos or rubia: A cosmetic skin lightening composition, comprising 0.1-50 % by weight of an extract of plants from the families of Symplocos, Rubia or a mixture thereof....

20060228310 - Zinc oxide: A dispersion containing zinc oxide particles having a dispersion particle size of (i) median volume particle diameter in the range from 70 to 130 nm, (ii) less than 16% by volume of particles having a volume diameter of less than 35 nm below the median volume particle diameter, and (iii)...

20060228313 - Method of cosmetic depigmentation care by applying at least one aurone: at least one aurone or a natural or synthetic derivative of aurone, or an analogue of aurone, in which the independent phenyl ring can be substituted by a heterocycle of pyrrole, imidazole, triazole, pyridine, furan, or thiophene type, is disclosed as a cosmetic agent, or as an active substance, for...

20060228314 - Cosmetic compositions containing phenyl silicones: The invention relates to cosmetic compositions containing certain phenyl silicones and the use of such silicones in improving the properties of cosmetic compositions....

20060228315 - Long-lasting liquid color formulations: Embodiments include a liquid colorant composition that is water-based. Certain liquid lip color embodiments include a composition having water and shellac. The composition may also include a neutralizer such as triethanolamine to neutralize the shellac. The composition may also include PPG-17/IPDI/DMPA copolymer. The composition may also include an emulsifier such...

20060228318 - Elastomer-forming barrier preparation: A method and preparation for application to the skin (stratum corneum). The preparation includes a silicone composition which is highly viscous on application and which, after application, cures, by crosslinking, into a soft and skin-friendly elastomer which adheres to the skin....

20060228320 - Agent for therapy or treatment of wound: The present invention has an object of revealing an epidermis regeneration effect of various chitin derivatives and providing an agent for therapy or treatment for wound which can be clinically used effectively. According to the present invention, it has been evidenced that N-acetyl-D-glucosamine has an effect of promoting proliferation of...

20060228319 - Personal cleansing and shaving films: Personal care composition in the form of a dry film useful in cleansing or shaving. The film includes at least one water soluble polymer in an amount of about 45 to about 82 weight %, based on total weight of dry film, and, when used for cleansing, at least one...

20060228321 - Topical treatment of ingrown hairs: This invention relates to improved compositions and methods for preventing or inhibiting the development of ingrown hairs or razor bumps in skin subjected to hair removal techniques by applying compositions containing sebum reduction agents; keratolytic agents and anti-inflammatory agents....

20060228316 - Hair relaxer compositions utilizing bioactive glass: A composition used for relaxing/straightening hair containing: (a) at least one hydroxide generator in an amount sufficient to relax/straighten keratin fibers; (b) at least one bioactive glass component; and (c) optionally, at least one complexing agent....

20060228322 - Method for improving conversion rate of oil soluble unsaturated lipids into water-soluble lipids: Disclosed relates to a method for improving a conversion rate of oil soluble unsaturated lipids into water-soluble lipids and, more particularly, to a method for improving a conversion rate of oil soluble unsaturated lipids into water-soluble lipids that forms an unsaturated lipid-chloride derivative having an increased reaction activity by using...

20060228317 - Graft polymers and use thereof in cosmetic formulations: The invention relates to graft polymers obtainable by free-radical graft polymerization of a) at least one N-vinyl-containing monomer b) optionally one or more further copolymerizable monomers onto a polymeric graft base c), which comprises at least one compound from the group c1) and at least one compound from the group...

20060228323 - Compositions for treating and removing noxious materials malodors and microbes, and methods of use and preparation thereof: A composition for removing noxious or malodorous ingredients from materials containing the same, the composition comprising an amphoteric compound; solvent; a compound selected from the group consisting of acids, salts of the acids and combinations thereof; and water, and wherein the relative amounts of each of the components present is...

20060228324 - Decorative printing on polymeric gel air freshener and methods: The present invention relates to provide decorative printing on a surface of polymeric gel materials. The printing methods can be pad printing, or screen-printing and heat transfer printing. The polymeric gel material is also capable of releasing a fragrance. The gel air freshener can be hang on the rear mirror...

20060228325 - Water soluble multi-biotin-containing compounds: Water-soluble discrete multi-biotin-containing compounds with at least three (3) biotin moieties are disclosed. The water-soluble biotin-containing compounds may additionally comprise one or more moieties that confer resistance to cleavage by biotinidase or that is cleavable in vitro or in vivo. The discrete multi-biotin-containing compounds may include a reactive moiety that...

20060228326 - Active specific immunotherapy of cancer metastasis: The present invention provides for the treatment of a subject with occult brain metastasis. The treatment relies on administering to the subject a composition comprising an immunomodulatory polypeptide and a baculovirus-insect cell preparation. This composition has a unique ability to generate an anti-tumor immune response that is able to cross...

20060228327 - Cc-chemokine mutants against liver diseases: CC-Chemokine mutants having reduced Glycosaminoglycans (GAG)-binding properties are effective against liver fibrotic inflammatory and/or autoimmune diseases. Particularly preferred are the mutants of CCL5/RANTES having reduced GAG-binding properties....

20060228330 - Dominant negative proteins and methods thereof: The invention relates to novel proteins with TNFSF antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNFSF-related disorders....

20060228329 - Homogeneous preparations of il-31: Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity....

20060228328 - Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins: The present invention relates to complexes and fusion proteins comprising an acute phase protein and an antigenic molecule, for use in the treatment or prevention of a disease. The invention specifically provides for complexes comprising an acute phase protein noncovalently bound to, or alternatively crosslinked to, an antigenic molecule. The...

20060228331 - Il-21 derivatives and variants: The invention provides derivatives of IL-21 or variants thereof, methods of producing such variants, new variants of IL-21, and various methods of using such molecules....

20060228332 - Assembly and folding of fc-interferon-beta fusion proteins: Disclosed are Fc-interferon-beta (Fc-IFN-β) fusion proteins and nucleic acid molecules encoding them. The Fc-IFN-β fusion proteins include variants of the interferon-beta (IFN-β) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using...

20060228333 - Methods for control of tumors and chronic infections by modulating immunologically informed carriers homing to tolerogenic organs or tissues: Methods for treating a patient after transplantation of a liver are presented which facilitate acceptance of the donor liver and treat the underlying disease or disorder that led to the transplant. A patient with a chronic viral infection is treated by inducing tolerance to the donor liver and suppressing tolerance...

20060228336 - Human prolyl isomerase 1 (pin 1) promoter and uses thereof: PIN1 transcriptional regulatory sequences (TREs) and vectors comprising the same are provided. These include replication competent vectors and replication incompetent vectors. PIN1 TREs provide for transcriptional regulation dependent upon transcription factors that are specifically active in cancer cells. The PIN1 TREs may be used as a vehicle for introducing new...

20060228334 - Modified adenoviral fiber with ablated to cellular receptors: The present invention concerns a modified adenoviral fiber containing at least one mutation affecting one or more amino acid residue(s) of said adenoviral fiber interacting with at least one glycosaminoglycan and/or sialic acid-containing cellular receptor, as well as a trimer of such a modified adenoviral fiber. The present invention also...

20060228335 - Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof: DNAs encoding rhesus monkey carcinoembryonic antigen (rhCEA) have been isolated, cloned and sequenced. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant...

20060228343 - Cardiac glycoside resistant non-immunogenic selection marker: A recombinant Na+, K+-ATPase α1-subunit protein resistant to cardiac gIycosides, e.g. oubain, is disclosed, as well as methods for its production and use. The resistance to cardiac glycosides are obtained b y alterations in the region situated between and including the amino acids 65-133. Such recombinant protein and nucleic acid...

20060228344 - Cell-containing preparations: The present invention provides a cell-containing preparation comprising cells containing a DNA having a base sequence represented by SEQ ID NO:1 or 2, or a DNA hybridizable with a DNA having a base sequence represented by SEQ ID NO:1 or 2 under stringent conditions, and a fibrous protein. The cell-containing...

20060228342 - Method for generating antigen-presenting cells: Described is a method for the generation of antigen-presenting cells (APC), preferably bone marrow-derived dendritic cells (BMDC) or peripheral blood-derived dendritic cells, as antigen carrier having immunostimulatory properties for anti-infective treatment comprising the steps of (a) pulsing the APC with antigen and (b) treating the APC with a CpG oligonucleotide....

20060228337 - Use of bacilli bacteria in order to produce a composition for the prevention of vertebral compression syndrome in salmonids: The invention relates to the use of cells of at least one strain of bacteria belonging to the Bacilli class for the production of a composition that is intended to prevent vertebral compression syndrome in fish from the salmonid family....

20060228340 - Hematopoietic stem cells treated by in vitro fucosylation and methods of use: A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an α1,3-fucosyltransferase, e.g., α1,3-fucosyltransferase VI, is used in vitro to treat cord blood-derived hematopoietic stem cells to convert non-functional PSGL-1 or other...

20060228338 - Isolated/cloned human nt2 cell lines expressing serotonin and gaba: Human cells isolated and/or cloned from human NT2 cells for expressing serotonin (5HT) and gamma-aminobutyric acid (GABA) are disclosed. These cells can be used as cellular minipumps to release serotonin and/or GABA to treat various neurological diseases, conditions, or disorders, particularly neurodegenerative disorders and the consequences of brain and spinal...

20060228339 - Methods of preparing transplantable product for treatment of skin defects: A method for preparing a tissue culture insert that is used for constructing a transplantable graft of an engineered tissue equivalent comprising living main functional cells, stromal cells and tissue matrix on/in a biological supporting membrane for treatment of body tissue defects....

20060228341 - Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof: The invention is in the area of pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof. In particular, the invention includes isolated adipose tissue derived stromal cells that have been induced to express at least one phenotypic characteristic of a neuronal, astroglial, hematopoietic progenitor, or hepatic cell....

20060228345 - Osteogenesis promoter: It is intended to provide an osteogenesis promoter capable of promoting osteogenesis by promoting the differentiation of osteoblasts, and foods, drinks, drugs or feeds for promoting osteogenesis. Namely, an osteogenesis promoter capable of promoting osteogenesis by promoting the differentiation of osteoblasts which comprises, as the active ingredient, lactoperoxidase and/or a...

20060228346 - Constitutively active phosphatidylinositol 3-kinase and uses thereof: The invention provides a method of producing a constitutively active phosphatidylinositol 3-kinase (PI 3-kinase) comprising the catalytic p110 subunit covalently attached at the N-terminus to the iSH2 region of the regulatory subunit, p85. The invention discloses one form of the constitutively active kinase, p110*, which functions independently of growth factor...

20060228347 - Antitumor agent and dnase: An antitumor agent comprising as an active ingredient a DNase, and novel DNases are disclosed. The novel DNases are derived from human stomach cancer cell line MKN-28 or human cervical cancer cell line HeLa, and do not act on normal cells but specifically act on cancer cells....

20060228348 - Targeting of glycoprotein therapeutics: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In...

20060228349 - Anti-addl antibodies and uses thereof: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also...

20060228350 - Framework-shuffling of antibodies: The present invention relates to methods of reengineering or reshaping antibodies to reduce the immunogenicity of the antibodies, while maintaining the immunospecificity of the antibodies for an antigen. In particular, the present invention provides methods of producing antibodies immunospecific for an antigen by synthesizing a combinatorial library comprising complementarity determining...

20060228351 - Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor: An object of the present invention is to provide a method for inducing differentiation and/or promoting proliferation of regulatory T cells, a method for suppressing the transendothelial cell migration of immunocytes, a method for suppressing immunity using these methods, and a pharmaceutical composition to be used for these methods. Provided...

20060228352 - Trail and methods of modulating t cell activity and adaptive immune responses using trail: Methods of modulating a T cell response are provided. Methods include, among other things, contacting a T cell that expresses TNF-related apoptosis-inducing ligand (TRAIL, Apo-2L) or TRAIL receptor (DR4 or DR5) with a molecule that binds to TRAIL (Apo-2L), a molecule that binds to TRAIL receptor (DR4 or DR5), or...

20060228354 - Modified adamts4 molecules and method of use thereof: The present invention relates to modified ADAMTS4 proteins having improved stability comparing to the corresponding native, unmodified proteins. The modified ADAMTS4 proteins can be expressed and isolated in large quantities, thus allowing further characterization of the proteins, such as crystallographic and enzyme kinetic studies. The purified, stable proteins would also...

20060228353 - Pth1r and pth3r receptors, methods and uses thereof: The present invention relates to novel parathyroid hormone (PTH) and parathyroid hormone related protein (PTHrP) receptors (PTH1R and PTH3R) isolated from zebrafish. The receptors of the present invention share homology with previously identified parathyroid hormone (PTH)/parathyroid related protein (PTHrP) receptors. Isolated nucleic acid molecules are provided encoding the zebrafish PTH1R...

20060228355 - Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor: The present invention relates to antibodies directed to Epidermal Growth Factor Receptor that are single domain antibodies Camelidae VHHs. It further relates to methods of of use of said polypeptides....

20060228356 - Composition and method for treating lupus nephritis: The present invention provides novel isolated BFLP0169 polynucleotides and polypeptides encoded by the BFLP0169 polynucleotides. Also provided are the antibodies that immunospecifically bind to a BFLP0169 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the BFLP0169 polypeptide, polynucleotide or antibody. The invention additionally provides methods in...

20060228357 - Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as...

20060228359 - Antibodies to myeloid progenitor inhibitory factor-1 (mpif-1): There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine β8 (CKβ8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-γ and chemokine β1(CKβ1 or ckb-1)), and a macrophage inhibitory protein-4...

20060228358 - Antibody molecules having specificity for human il-1 beta: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1β, the uses of the antibody molecule and methods for producing said antibody molecule....

20060228360 - Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12: The present invention provides a method for enhancing oral tolerance to an antigen associated with an autoimmune disease in a subject having the autoimmune disease comprising orally administering to the subject an antigen associated with the autoimmune disease and administering an inhibitor of interleukin-12 in amounts sufficient to enhance oral...

20060228361 - Dicer interacting proteins and uses therefor: Dicer (e.g., DCR-1) interactors are disclosed as are methods to positively or negatively modulate Dicer activity. Uses of Dicer interactors as drug targets are featured. Also featured are uses of Dicer interactors and modulators of same to modulate various Dicer functions in vitro, in cell cultures, and in vivo....

20060228362 - Novel protease gene: A neurolysin-like substance having an activity of degrading a synthetic substrate Mcc-Pro-Leu-Gly-Pro-D-Lys(DNP)—OH, diagnostic means and pharmaceutical compositions employing it....

20060228363 - Monoclonal antibody therapy for pancreas cancer: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer....

20060228365 - Protein and gene involved in myocyte differentiation: The invention relates to antibodies that bind to novel polypeptides expressed in immortalized cells, skeletal muscles and undifferentiated cells. In addition, the polypeptides inhibit the differentiation of myoblasts into myotubes....

20060228364 - Serum albumin binding peptides for tumor targeting: Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion....

20060228366 - Tumor specific monoclonal antibodies: The invention provides tumor-specific human monoclonal antibodies and functional fragments. Also provided are nucleic acids encoding tumor-specific human monoclonal antibodies and functional fragments. A method for reducing neoplastic cell proliferation is also provided. The method consists of administering an effective amount of a tumor-specific human monoclonal antibody or functional fragment....

20060228367 - Antibodies against mammalian metapneumovirus: The present invention provides antibodies that immunospecifically bind to a polypeptide of a mammalian metapneumovirus, compositions comprising said antibodies, and methods for producing such antibodies. In particular, the invention provides monoclonal antibodies that immunospecifically bind to the F protein of human metapneumovirus and that neutralize human metapneumovirus. The invention also...

20060228368 - Method of protecting against staphylococcal infection: A method of preventing or treating staphylococcal bacterial infection in an individual is disclosed. A vaccine based on a conjugate the 336 polysaccharide antigen can be used for active protection in individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection,...

20060228369 - Stabilization and preservation of temperature-sensitive vaccines: The present invention relates to the use of temperature protective agents to protect temperature sensitive vaccines. Such agents can be used to protect vaccines from degradation that results from exposure to freezing conditions or hot environments. Such agents can also be used to help reduce or prevent degradation or contamination...

20060228370 - 7a5/prognostin and use thereof for the diagnostic and therapy of tumors: The present invention refers to the nucleic acid sequence encoding for the polypeptide of 7a5/Prognostin and to its uses, in particular for the tumour diagnostics and tumour therapy of metastasising tumours....

20060228371 - Immunological control of beta-amyloid levels in vivo: An antibody and vectorized antibody, capable of crossing the blood brain barrier, which catalyze hydrolysis of β-amyloid at a predetermined amide linkage are described. The antibody preferentially binds a transition state analog which mimics the transition state adopted by β-amyloid during hydrolysis. Also described are methods for sequestering free β-amyloid...

20060228372 - Methods for modulating angiogenesis: Recombinant plasminogen activator inhibitor-1 (PAI-1) isoforms which lack the reactive center loop and contain the complete heparin-binding domain or lack at least a portion of the heparin-binding domain are described. The rPAI-1 isoforms disclosed herein may be used to modulate angiogenesis through blocking release of VEGF from a VEGF-heparin complex....

20060228373 - Mycoplasma hyopneumoniae bacterin vaccine: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response...

20060228374 - Oral dna composition for hepatitis b virus chronic infection: The present invention provides an oral DNA composition for improving an impaired immunity associated with chronic infection of hepatitis B virus (HBV) and for suppressing transgene expression for a protrated period of time comprising an attenuated strain of bacterial cells which preferentially target phagocytic cells of the intestinal mucosa, and...

20060228375 - Induction of mucosal immunity by vaccination via the skin route: Methods for generating an immune response at a mucosal surface are described. Compositions suitable for use in the methods for generating an immune response at a mucosal surface are also described. In addition, methods for treating or preventing a disease caused by the entry of a pathogen into the body...

20060228376 - Virosome-like-particles: The invention relates to the production of virosome-like-particles. The invention provides a method for producing a virosome-like-particle comprising contacting an enveloped virus with a solution containing a short-chain phospholipid allowing solubilisation of the viral envelope of said virus further comprising removing short-chain phospholipid from said solution allowing formation of a...

20060228377 - Gram-positive bacteria deprived of htra protease activity and their uses: The invention concerns bacteria strains, obtained from gram-positive bacteria whereof the genome size is not more than 3.2 Mb, and wherein the HtrA surface protease is inactive. Said strains are useful for expressing exported proteins of interest....

20060228379 - Novel microorganism pediococcus pentosaceus erom101, having immune enhancement, anticancer and antimicrobial activities: The present invention relates to a novel Pediococcus genus microorganism and more particularly, Pediococcus pentosaceus EROM101 (KCCM-10517) originated from human intestines having immune enhancement, anticancer and antiviral activities and a use thereof. Due to its excellent immune enhancement, anticancer and antimicrobial activities by activating macrophages/spleen cells and inducing gut immunity,...

20060228378 - Surface proteins of leptospira: The invention relates to Leptospiral surface proteins, and the nucleic acid molecules which encode them. Various uses are described, including immunoprophylactic, diagnostic and therapeutic methods....

20060228380 - Multivalent pneumococcal polysaccharide-protein conjugate composition: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic...

20060228381 - Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation: A process for reducing the protein content and preserving the capsular polysaccharide content in a complex cellular Streptococcus pneumoniae lysate broth prior to purification is described. Utilizing pH reduction after cellular lysis has resulted in a purified polysaccharide that consistently meets the protein specification, and higher recovery yields of polysaccharide...

20060228382 - Lipoglycan compositions and methods of treating parasitic infections: A composition for and a method of eliciting in a vertebrate a protective immune response against an eukaryotic parasite are disclosed. The method includes administering to the vertebrate a composition having a carrier group coupled to an oligosaccharide obtained from a lipoglycan found on the surface of an eukaryote. The...

20060228384 - Control of biofilm with a biofilm inhibitor: The present invention provides methods for preventing, reducing, inhibiting or removing bacterial biofilm. The present invention also provides methods for controlling acne and chronic bacterial infections. The present invention further provides a method for identifying agents that prevent, reduce, inhibit or remove bacterial biofilm....

20060228383 - Stable pharmaceutical composition of fluoroether compound for anesthetic use method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound: The present invention has as objective the stabilization of a fluoroether compound against degradation by acid substances. The stabilizers proposed are selected among propylene glycol, polyethylene glycol, hexylene glycol, 1,3-butylene glycol and a saturated cyclic alcohol preferably menthol and are used for preparing stable pharmaceutical compositions of a fluoroether compound....

20060228385 - Sustained release of microcrystalline peptide suspensions: The invention relates to a microcrystalline aqueous suspension of a peptide salt selected from the group consisting of Ac—D—Nal—D—Cpa—D—Pal—Ser—Tyr—D—Hci—Leu—Ilys—Pro—D—Ala—NH2trifluoroacetate and Ac—D—Nal—D—Cpa—D—Pal—Ser—Tyr—D—Hci—Leu—Ilys—Pro—D—Ala—NH2 sulfate. The invention also relates to methods of preparing the suspension, lyophilized compositions formed from the suspensions, and sustained release formulations that include the suspensions....

20060228386 - Polymeric microstructures: Methods for producing and using polymeric microstructures having a pre-determined geometry (e.g., rectangular prism, cube), and pre-determined surface characteristics are disclosed herein. The polymeric microstructures described herein are particularly useful as microcarriers in cell culture applications because they provide high surface areas, and improved surface/volume ratios over currently available microstructures,...

20060228387 - Dihydronepetalactams and n-substituted derivatives thereof: Dihydronepetalactams and N-substituted derivatives thereof are prepared by alkylation of metallated lactams. Dihydronepetalactams and N-substituted derivatives thereof have utility as insect repellents....

20060228388 - Method for controlling an insect species using a synthetic trail pheromone mimic: The invention provides a method for controlling a caterpillar species using a synthetic trail pheromone mimic....

20060228390 - Intravitreal implant: A device and method for drug delivery is shown. In particular, a drug delivery device for implanting in an eye is shown. Advantages of drug delivery devices shown include an increased surface area allowing an increased drug dosage from a delivery mechanism such as a drug-containing coating. Another advantage of...

20060228391 - Methods of tissue repair and compositions therefor: The present application discloses matrix compositions to support the repair of tissue defects such as an injury to tendon tissue, ligament tissue, vascular tissue, dermal tissue, or muscle tissue. A matrix described herein comprises a polyester polymer entangled with a polysaccharide polymer. Also disclosed are methods of preparing a matrix,...

20060228389 - Vascular implant device: Vascular smooth muscle cells (VSMCs) adhere to and orient along micropatterned grooves having a depth of 1 to 10 μm and a width of 1 to 20 μm that are imposed on the surface of a vascular implant device. The VSMCs maintain an elongated morphology and reduced proliferation resulting in...

20060228392 - Nell-1 enhanced bone mineralization: This invention pertains to the discovery that the human NELL-1 gene induces or upregulates bone mineralization. The NELL-1 gene or gene product thus provides a convenient target for screening for modulators of bone mineralization. In addition, NELL-1 can be used to facilitate repair of bone fractures and/or to generally increase...

20060228393 - Ocular solutions: Ocular solutions containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the...

20060228394 - Ocular solutions: Ocular solutions containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the...

20060228396 - Arginine-containing compositions and methods for increasing blood flow using same: A composition for increasing blood flow is provided, wherein side effects such as lowering of blood pressure are reduced and blood flow is effectively increased in the capillaries. A composition containing arginine in an amount from 25 mg/kg body weight to 150 mg/kg body weight is also provided. A food...

20060228397 - Dietary supplement, and methods of use: One aspect of the invention provides dietary fiber compositions comprising effective amounts of glucomannan, xanthan gum, and alginate to produce a desired viscosity. The invention also provides food products comprising an effective amount of a dietary fiber composition. In other aspects, the invention provides methods for preparing a dietary fiber...

20060228395 - Vitamin e phosphate/phosphatidylcholine liposomes to protect from or ameliorate cell damage: Compositions containing liposomes may be prepared by sonicating the liposomes in a clear liquid to obtain a clear composition of matter. Beverages prepared are clear and visually appealing. Compositions of the invention help to protect from cell damage....

20060228398 - Compositions, methods and uses for a novel family of peptides: The present invention includes compositions and methods for the characterization and use of novel peptide from Brevibacillus sp., and peptides related thereto, including an isolated and purified, heat stable, amino terminus-methylated, carboxy-terminus reduced peptide that have two or more D-amino acids used as, e.g., an antimicrobial or even a feed...

20060228399 - Taste masked veterinary formulation: A method of producing a self-take anthelmintic that includes active components that are undesirable to at least one sense of a target animal. The active ingredients including praziquantel are mixed with artificial beef and yeast components and subjected to a first compression. The resulting rough tablet is then ground to...

20060228400 - Thermotolerant phytase for animal feed: The invention provides a synthetic phytase polynucleotide which is optimized for expression in plants and which encodes at thermotolerant phytase, as well as isolated thermotolerant phytase enzyme. Also provided are feed or food products comprising a thermotolerant phytase, and transgenic plants which express the thermotolerant phytase. Further provided are methods...

20060228401 - Layered aligned polymer structures and methods of making same: This invention includes a method of producing a thin, oriented layer of polymer material. The material is preferably produced by the method of introducing a shearing flow to a free surface in a predominantly monomeric solution of the self-assembling polymer sub-units, and inducing polymerization or growth of the monomer while...

20060228404 - Compositions and methods for treatment of hypertrophic tissues: The present invention provides compositions and methods for treatment of conditions and diseases associated with excessive or inappropriate noncancerous tissue growth. In certain embodiments of the invention the compositions and methods are used for treatment of benign prostatic hyperplasia. In certain embodiments of the invention the composition comprises a tissue-selective...

20060228407 - Enhanced delivery via serpin enzyme complex receptor: Serpin enzyme complex receptors are used as targets for therapeutic drugs in the lungs and brain tissue. any lung or brain disease and any therapeutic drug can be targeted to the lung or brain by use of ligands which specifically bind to the receptors. Complexes for delivery may include proteins,...

20060228403 - Nutritional supplements for cardiovascular health: An admixture containing as active ingredients omega-3 polyunsaturated fatty acids selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and linoleic acid (LNA), curcumin, B complex vitamins selected from folic acid, B6 and B12, antioxidant vitamins selected as vitamin C and vitamin E and ubiquinone. This compound is being designed for...

20060228405 - Phospholipid-based pharmaceutical formulations and methods for producing and using same: Pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, pharmaceutically acceptable salts thereof, or prodrugs thereof. In specific embodiments, the pharmaceutically active compounds are ansamycins and the overall formulation is substantially devoid...

20060228402 - Techniques for forming a lipid bilayer membrane: A method for forming a lipid bilayer membrane is provided, the method comprising forming a layer of lipid molecules on a liquid surface at an air-liquid interface between a liquid volume and an air volume. An aperture is moved from the liquid volume to the air volume through the layer...

20060228406 - Transfection reagent for non-adherent suspension cells: The present invention discloses liposomal transfection reagents for delivery of macromolecules and other compounds into cells, particularly non-adherent suspension cells. They are especially useful for the DNA-dependent transformation of cells. Methods for their preparation and use as intracellular delivery agents are also disclosed....

20060228408 - Drug delivery system: An oral drug delivery system which comprises a biliquid foam comprising: from 1 to 20% by weight of a continuous hydrophilic phase, from 70 to 98% by weight of a pharmaceutically acceptable oil which forms a discontinuous phase, the said pharmaceutically acceptable oil having dissolved or dispersed therein a poorly...

20060228410 - Flavored taste-masked pharmaceutical formulation made using a one-step coating process: The present invention encompasses a flavored and taste-masked pharmaceutical composition comprising a plurality of pharmaceutically acceptable cores, such as microspheres, said pharmaceutically acceptable cores comprising etoricoxib, wherein the pharmaceutically acceptable cores are coated with a flavored taste-masking coating solution in a convenient one-step process....

20060228411 - Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs: Pharmaceutical compositions having improved dissolution profiles for drugs therein is disclosed....

20060228409 - Scored tablet: An object of the present invention is to provide a dividable tablet that is easily and accurately divided without any particular limitation on dividing method thereof and has superior strength. That is, the present invention provides a dividable tablet whose lower surface is a curved surface gradually rising from the...

20060228412 - (-)-hydroxycitric acid for delaying gastric emptying: The inventors have discovered that food and pharmaceutical compositions containing (−)-hydroxycitric acid, its salts, amides and esters can be employed for delaying gastric emptying and increasing receptive relaxation for preventing and treating diverse conditions. The invention provides for HCA-containing compound useful to delay gastric emptying and increase receptive relaxation for...

20060228413 - Controlled release venlafaxine formulations: In certain embodiments, the present invention is directed to a controlled release oral dosage form comprising: a therapeutically effective amount of venlafaxine or a pharmaceutically acceptable salt thereof and a controlled release material; wherein the amount of venlafaxine or pharmaceutically acceptable salt thereof released at 1 hour in 900 mL...

20060228414 - Method for the preparation of controlled release formulations: The methods disclosed herein are of use for the production of controlled release compositions. In particular, the methods provide the contacting of an organic phase containing a bioactive agent and a polymer with an aqueous phase containing an organic ion to create controlled release compositions containing bioactive agents. The present...

20060228415 - Modified release tablet of bupropion hydrochloride: A modified-release tablet of bupropion hydrochloride comprising (i) a core comprising an effective amount of bupropion hydrochloride, a binder, a lubricant; and (ii) a control releasing coat surrounding said core; and (iii) a moisture barrier surrounding said control releasing coat, wherein the modified-release tablet is bioequivalent to Wellbutrin® or Zyban®/Wellbutrin®SR...

20060228416 - Methods for modulating topical inflammatory response: A method of modulating topical inflammatory response is disclosed. The method generally includes the selective removal of certain proteins, e.g., one or more cytokines such as interleukin-1β (IL-1β) and/or interleukin-6 (IL-6), from a topical site without substantially altering the local concentrations of other proteins that may be present at or...

20060228417 - Mucoadhesive composition comprising polyacrylate and chemoattractant: The invention relates to a mucoadhesive pharmaceutical composition comprising an acrylic acid containing polymer and a chemoattractant wherein the pH of the composition is 6 or less....

20060228418 - Topical ointment and method for making and using same: A topical ointment comprises a base material of plasticized hydrocarbon gel and methylcellulose in which are dispersed a plurality of microbubbles containing liquid. The microbubbles containing liquid are encapsulated by the base material to form microencapsulations which are dispersed in the base material to form a hydrogel. Application of the...

20060228421 - Device for moving magnetic nanoparticles through tissue: The movement of magnetically responsive nanoparticles through a membrane is significantly enhanced by using a varying magnetic field gradient. The magnetic field varies in intensity and/or direction and can be achieved by mechanically varying the position of a magnet with respect to the membrane, or by oscillating the strength of...

20060228420 - Pharmaceutical compositions comprising microparticles for delivery into neurons: A method is provided for the delivery into a neuron of a microparticle of average particle diameter 0.5 μm containing a pharmaceutically active substance, comprising the administration of said particle to said neuron. Also provided are methods for the treatment of diseases of the nervous system comprising the use of...

20060228419 - Solvent-free process for preparation of hydrophilic dispersions of nanoparticles of inclusion complexes: The invention provides a solvent-free process for the preparation of a hydrophilic dispersion comprising nanoparticles of an hydrophilic inclusion complex consisting essentially of nanosized particles of an active compound and an amphiphilic polymer which wraps said active compound such that non-valent bonds are formed between said compound and said polymer...

20060228422 - Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration: The present invention relates to microcapsules with a double-layer of natural polysaccharides—chitosan and alginate—gelified and stabilized by means of a divalent ion containing inside at least one biologically active substance. The microcapsules of the invention can be employed as carriers for the oral administration of biologically active substances, also associated...

20060228423 - Cartilage composition for transplantation: The invention relates to provide a cartilage composition for transplantation which contains a chondrocyte tissue per se formed by culturing chondrocytes; and a method of transplanting the cartilage using the same. The cartilage composition obtained by the invention is free from any risk of viral or bacterial infections and contains...

20060228424 - Phosphorus binder for treatment of kidney disease: The present invention relates to oral compositions which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The dietary supplements and pharmaceutical products...

20060228425 - Compositions and methods for destabilizing lysosomes to increase oncogenic or aberrant protein degradation: The present invention relates to compositions and methods for destabilizing lysosomes to increase the degradation of oncogenic or aberrant proteins for the prevention and treatment of disease. Methods for identifying agents which destabilize lysosomes are also provided as are agents identified in accordance with the screening method....

20060228428 - A composition for preventing plant diseases resulted from infection of plant pathogens and a method for preparing the same: The present invention relates to a composition for preventing at least one plant disease resulted from infection of plant pathogens and a method for preparing the same. Particularly, the composition contains extract of at least one plant selected from the group consisting of Coptis chinensis Franch., Phellodendron genus plant, Sanguinaria...

20060228426 - Plant extracts for treatment of angiogenesis and metastasis: Extracts from plant material, or semi-purified/purified molecules or compounds prepared from the extracts that demonstrate the ability to modulate one or more cellular activities are provided. The extracts are capable of slowing down, inhibiting or preventing cell migration, for example, the migration of endothelial cells or neoplastic cells and thus,...

20060228427 - Solid mucoadhesive composition: An adhesive solid therapeutic composition containing an active ingredient which is an extract of a plant selected from the group consisting of Sambucus nigra, Centella asiatica and Echinacea purpurea, or mixtures thereof and excipients, said excipients comprising (i) a bulk ingredient (ii) an adhesive polymer of acrylic acid and (iii)...

20060228429 - Pharmaceutical composition and method for the treatment and prevention of prostatic hyperplasia and prostatitis using roystonea regia (royal palm) fruits: The invention relates to a novel pharmaceutical composition and to the method of producing same from the fruits of the royal palm (Roystonea regia) in order to prevent and/or treat benign prostatic hyperplasia (BPH) and prostatitis as well as alopecia and hirsutism. The inventive composition comprises a mixture of free...

20060228430 - Novel method for preparing processed ginseng to obtain increased amount of ginsenoside rg5: The present invention relates to a processing method for preparing pharmacologically potent ginseng product and the extract therefrom which could provide abundant amount ginsenoside Rg5 showing various pharmacological activities with applying selected range of pressure and temperature into the method and therefore the composition comprising the processed ginseng and the...

20060228431 - Nutriceutical tea: Provided are compositions of plant material and a purified nutritional supplement or pharmaceutical adhering to the plant material with a binder. Also provided are potable beverages resulting from steeping or brewing these compositions. Further provided are delivery systems for a nutritional supplement or pharmaceutical having the above composition in a...

20060228432 - Alpha-glucosidase inhibitors from a natural source: The present invention relates to a method for providing α-glucosidase inhibition to a subject by administering a pharmaceutical composition comprising a α-glucosidase inhibitory agent selected from pipataline (formula 1a), sesamin (formula 1b), pellitorine (Formula 1c), guineensine (Formula 1d) and brachystamide-B (formula 1e) having therapeutic application for diabetes mellitus, cancer, viral...

20060228433 - Method for restoration of gap junctional intercellular connection: A method for restoring gap junctional intercellular communication (GJIC) in the cells of a mammal, including humans. The method includes administering to mammals who have been determined to have a mutation in the ras gene a phytosterol to restore GJIC. The phytosterol can be β-sitosterol, stigmasterol, or mixtures of these...

20060222587 - Hybrid inorganic nanoparticles, methods of using and methods of making: The invention provides hybrid inorganic nanoparticles, methods of making the hybrid inorganic nanoparticles and methods of using the hybrid inorganic nanoparticles....

20060222588 - Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent: A medical agent comprising a reagent conjugated to an anti-lymphoma antibody is disclosed, as well as a kit containing said medical agent, use of said medical agent, and a method for treatment of lymphoma. The reagent may comprise an effector, e.g. an antitumor agent or a diagnostic marker, and an...

20060222589 - Directed complementation: A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary...

20060222590 - Directed complementation: A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary...

20060222591 - Method for monitoring early treatment response: Disclosed is a method for monitoring early treatment response of a cancer treatment comprising measuring by magnetic resonance spectroscopy (MRS), for example, proton MRS, the amount of Choline present in the endomembranes of the cancerous tissue before and after treatment; the treatment comprises administration of a cytotoxic therapy, whereby a...

20060222595 - Nanoparticles for therapeutic and diagnostic applications: This document provides materials and methods related to nanoparticles. For example, nanoparticle compositions, methods for making nanoparticle compositions, and methods for using nanoparticle compositions are provided. In some cases, the nanoparticles are gold (e.g., colloidal gold) nanoparticles. A nanoparticle can include one or more agents linked to its surface, such...

20060222593 - Peptide-chelate conjugates: A peptide-chelate with affinity for the ST receptor is disclosed, wherein the chelate is tetradentate. The peptide-chelate conjugate of the invention may be labelled with a radiometal to provide a metal complex. A radiopharmaccutical composition comprising the metal complex is provided, which is suitable for the diagnostic imaging of colorectal...

20060222594 - Smart magnetic nanosphere preparation and manufacturing method thereof: Disclosed are a targeting magnetic nanosphere preparation capable of diagnosing and treating tumors in mammals and a method of manufacturing the same. The smart magnetic nanosphere preparation contains magnetic nano-sized iron oxide nanoparticles, which can be detected by magnetic resonance imaging (MRI), as a core material. The core material is...

20060222596 - Non-degradable, low swelling, water soluble radiopaque hydrogel polymer: Hydrogel compositions prepared from amine components and glycidyl ether components are provided which are biocompatible and suitable for use in vivo due, in part, to their excellent stability....

20060222592 - Nanoparticles and methods of manufacturing nanoparticles for electronic and non-electronic applications: Binary or ternary nanoparticles containing a group I metal, a group VI non-metal, and perhaps a group III, IV, or V non-metal are produced using a single or multiple source precursor. A precursor and a surfactant are mixed, a solvent is added to the mixture, the mixture is heated at...

20060222597 - Buccal, polar and non-polar sprays containing propofol: Buccal aerosol sprays using polar and/or non-polar solvents have now been developed which provide propofol for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: propofol, a polar solvent and an optional flavoring agent; formulation II: propofol,...

20060222598 - Aerosol formulation for inhalation comprising an anticholinergic: c

20060222599 - Inhalative powder formulations containing the cgrp-antagonist 1 [n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine: Powdered preparations for pulmonary or nasal inhalation, containing the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) or a pharmaceutically acceptable salt thereof, processes for preparing them and the use thereof for preparing a pharmaceutical composition for the treatment of headaches, migraine and cluster headache....

20060222601 - Oral care compositions with color changing indicator: The invention describes color changing toothpastes and mouthwashes which contains acid-base indicator(s) for interaction with the oral cavity to provide a color change indicative of treatment time....

20060222600 - Oral care regimens and devices: Disclosed are various oral care devices and methods. One method includes introducing a composition into the oral cavity, wherein the composition includes a reactive species generating agent. Output from a light emitting element is directed at a portion of the soft tissue of the oral cavity for a period of...

20060222603 - Compositions having anti-dental caries function: The present invention relates to dietary compositions and oral compositions having an anti-dental caries function. The present invention provides dietary compositions and oral compositions having an anti-dental caries functions which contain a buffering agent having a pH buffering action in the oral cavity....

20060222602 - Oral and dental hygiene product: An oral and dental hygiene product comprising a) a composite material containing poorly water-soluble calcium salts in the form of nanoparticulate primary particles which are between 5 and 150 nm long and have a cross-section of between 2 and 50 nm, and protein constituents selected from proteins, protein hydrolysates and...

20060222604 - Method for bleaching teeth and bleaching agent for teeth: A method for bleaching teeth comprises steps of applying a solution containing nitrogen-deeped titanium oxide powder on a surface of teeth, and irradiating the applied part with light to bleach the teeth based on a photocatalytic action thus produced, and a bleaching agent for teeth suitable for carrying out the...

20060222605 - Sulfur-modified zinc oxide: The present invention relates to particles or powders of a compound of formula Zn1-yMyO1-xSx, wherein x has a value in the range from 0.01 to 0.08, M represents a divalent metal and y has a value in the range from 0 to 0.2, the compound having a wurtzite structure....

20060222606 - Translucent, sunscreening cosmetic foundation composition: e

20060222607 - Tricyclic quinoxaline and quinoline derivatives as uv filters: The invention relates to the use of quinoxaline derivatives of formula I, represented by formulas Ia and Ib, as photostable UV filters, in particular in cosmetic and pharmaceutical preparations for protecting the human epidermis or human hair against UV radiation, above all in the 280-400 nm range....

20060222608 - Edible tremella polysaccharide for skin care: It has been found that the polysaccharide isolated from a hot water extract of a Tremella mushroom without adding a chemical reagent has a novel effect of inhibiting melanin formation effects, so it can be used to lighten the spots on the skin when being applied to the skin. In...

20060222610 - Composition comprising metal oxides: A composition is provided comprising: (a) first metal oxide particles having a first number weighted average primary particle size from 1 nm to 50 nm; and (b) second metal oxide particles having a second number weighted average primary particle size which is greater than 50 nm and less than or...

20060222609 - Peptide-based body surface coloring reagents: Peptides have been identified that bind with high affinity to body surfaces, such as, hair, skin, nails, teeth, gums, and oral cavity surfaces. Diblock and triblock peptide-based body surface coloring reagents formed by coupling a body surface binding peptide to a pigment binding peptide, either directly or through a spacer,...

20060222611 - Compositions and methods for delivery of caffeine: Methods for delivery of caffeine, compositions including caffeine, and methods of making such compositions are disclosed. Generally, the method of delivering caffeine includes topically administering to a mucosal skin surface of a subject a dose of caffeine effective to increase alertness in the subject. The compositions generally include a lip...

20060222612 - Compositions of zirconium chloride complex and its method of manufacture: The invention discloses a process for preparing highly active aluminum zirconium tetrochlorohydrate glycine powder by forming aluminum chloride glycine and zirconium chloride glycine solution individually, and then blending such aluminum chloride glycine and zirconium chloride glycine together to form aluminum zirconium tetrochlorohydrate glycine....

20060222615 - Cosmetic preparation: e

20060222616 - Cosmetic composition comprising a and a lipopeptide: The present invention provides a cosmetic composition, comprising 0.1 to 5 mass % of a lipopeptide compound, and 0.1 to 20 mass % of a polyoxyethylene glyceryl ether fatty acid ester and/or a polyoxyethylene sorbit fatty acid ester. The cosmetic of the present invention, with an extremely low skin irritating...

20060222617 - Water-soluble cosmetic composition and method for manufacturing the same: A water-soluble cosmetic composition and the manufacturing method thereof are provided. The water-soluble cosmetic composition is obtained by a process as follows. First, a mixed solution is provided, wherein the mixed solution comprises about 0.1% to 30% by weight of ascorbic acid or derivatives thereof, and 0.1% to 10% water-soluble...

20060222613 - Hair treating agent: The present invention provides a hair treating agent that is applied after applying a reducing agent for straightening curly hair in straightening treatment of curly hair and uniformly softens hair without damaging. Specifically, the present invention relates to a hair treating agent that is applied after applying a reducing agent...

20060222618 - Reducing agent for straightening curly hair and process for straightening curly hair: The present invention aims to provide a reducing agent for straightening curly hair that can deal with various kinds of hair damage and various degrees of curling and a process for straightening curly hair, which does not cause breaking and insufficient straightening of curly hair. Specifically, the present invention relates...

20060222614 - Hair straightening compositions and methods: Compositions and methods for the straightening and defrizzing of mammalian hair containing alkyl polyglucosides (APGs) in an amount at least 15% by weight of the composition. Compositions are preferably included in hair care products such as shampoo, conditioner, styling gel or hairspray....

20060222620 - Composition for pharmaceutical or dietetic use for combating hair loss: The use of the polyamine known as spermidine, i.e., N-(3-aminopropyl) tetraminethylenediamine, as an active principle in the preparation of a composition for pharmaceutical or dietetic use in man for combating hair loss is disclosed....

20060222619 - Use of plant extracts for tinting the skin as a function of its phototype: The invention discloses a method for tinting, for coloring skin, or for increasing the tanned appearance of skin comprising the use of an extract of a plant from the family of Compositae or Asteraceae, preferably an extract of chicory (Cichorium intybus L.), and a method of screening a plant for...

20060222621 - Solid odor absorbers consisting of anodic oxide layers with active substance stored therein: Solid odor absorbers including a solid carrier with a nanostructured surface and, incorporated therein, active zinc ricinoleate as an odor absorber are provided....

20060222622 - Methods and compositions for preventing and treating radiation-induced skin reactions: Methods for preventing and treating radiation-induced skin reactions are disclosed. The methods generally include applying one or more hydrogel compositions to a topical site before, during, and/or after exposure to radiation. The hydrogel compositions generally include one or more electrolytes. In some embodiments, the hydrogel compositions can include a protein...

20060222623 - Composition for treating dry eye and related methods of manufacture and methods of use: The present invention is directed to a composition for treating dry eye comprising, in one embodiment, carboxymethylcellulose and a polyol. Such compositions have been found to alleviate the symptoms of dry eye and remain in the eye for a long period of time....

20060222624 - Detoxified tnf and method of preparing: The present invention provides for an immunogenic analogue of a human TNFα protein, wherein said analogue comprises an immunogenized monomeric TNFα polypeptide or TNFα di- or timer, and wherein the analogue further comprises a toxicity reducing or abolishing mutation selected from the group consisting of Y87S, D143N or A145R, the...

20060222626 - Modified tumor necrosis factor: Modifying TNF with polyethyleneglycol (PEG) having an approximate weight average molecular weight in the range of about 10,000 to about 40,000, preferably in the range of about 20,000 to 30,000, significantly increases the circulating half-life of the TNF while not increasing its toxicity. As a result, lower doses of the...

20060222625 - Therapeutic uses of allogeneic myeloid progenitor cells: Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed...

20060222628 - Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes and dna viruses: Methods are provided for treating or preventing infections by obligate intracellular prokaryotes, including mycoplasma, rickettsia and chlamydia, and DNA viruses, including herpes viruses, papillomaviruses, adenoviruses and hepatitis B virus. The methods involve the administration of 3:1 complexes of 3-hydroxy-4-pyrones with gallium, e.g., gallium maltolate. Therapies incorporating gallium maltolate in combination...

20060222627 - Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue: An implant such as a stent is coated with a biodegradable or non-biodegradable polymer having therein an antiproliferative/immunosuppressive agent and a compound which reduces the rate of metabolism of the antiproliferative/immunosuppressive agent thereby inhibiting restenosis....

20060222629 - Compositions and methods for delivery of genetic material: Methods of introducing genetic material into cells of an individual and compositions and kits for practicing the same are disclosed. The methods comprise the steps of contacting cells of an individual with a polynucleotide function enhancer and administering to the cells, a nucleic acid molecule that is free of retroviral...

20060222630 - Internal ribosome entry site of the labial gene for protein expression: The invention describes compositions and methods for recombinant protein expression in a wide range of cell types. The compositions comprise an IRES sequence from the Drosophila labial (lab) gene, or a variant or fragment thereof, or alternatively, a homolog of a lab IRES, or a variant or fragment thereof. Methods...

20060222631 - Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex: A protocol for use of growth factors to stimulate neuronal cell growth and activity in trkB receptor containing cortical tissues, including the entorhinal and hippocampal cortices. The method introduces exogenous growth factor, such as BDNF, NT-4/5 and NT-3, into the EC. The method is useful in therapy of defective, diseased...

20060222636 - Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells: The present invention includes compositions, methods and kits for non-nuclear transfer reprogramming an adult differentiated cell obtained from an adult tissue into an ES-like cell. The reprogrammed cell can be converted into an ES-like cell which can be re- or trans-differentiated into various differentiated cell types. The present invention further...

20060222635 - Methods and compositions for selecting cells with increased potency: The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides. In addition, the present...

20060222632 - Disinfection of foodstuffs: A method of disinfection of livestock is provided. The method comprises administering at least one bacteriophage in an effective amount to said livestock to reduce the number of Campylobacter spp present in the gastro-intestinal tract of said livestock. The bacteriophage are selected from CP8 (NCIMB Accession No. 41184) and CP34...

20060222634 - Amnion-derived cell compositions, methods of making and uses thereof: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived...

20060222633 - Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host: The invention includes compositions and methods for depleting and/or inactivating antigen presenting cells, or for otherwise impairing the biological function of antigen presenting cells, which compositions are useful for treatment of graft versus host disease and other immune diseases....

20060222637 - Proliferation of muc1 expressing cells: The present application discloses a method for stimulating or enhancing proliferation of a population of cells by activating MUC1 receptor on the cells....

20060222638 - Cholesterol biosynthesis pathway modulators and uses thereof: An isolated peptide comprising the amino acid sequence of SEQ ID NO: 2, or a variant, derivative and/or fragment thereof having the function of HMGCoA reductase inhibitor, phosphomevalonate inhibitor, reducing the accumulation of cholesterol in the cholesterol biosynthesis pathway and/or reducing the level of serum cholesterol. Also disclosed is a...

20060222641 - Method and composition for preventing or reducing edema, deep vein thrombosis and/or pulmonary embolism: The present invention relates to a composition and method for preventing or reducing edema, deep vein thrombosis (DVT), and/or pulmonary embolism by administering a combination of a fibrinolytic agent and an antioxidant. The composition is particularly useful for treating individuals prior to or during long term flights or other situations...

20060222640 - New pharmaceutical compositions for treatment of thrombosis: The present invention relates to novel pharmaceutical compositions comprising at least one direct thrombin inhibitor and at least one additional active compound selected from the groups consisting of platelet inhibitors, low molecular weight heparins (LMWH) and heparinoids as well as unfractionated heparin, factor Xa inhibitors, combined thrombin/factor Xa inhibitors, fibrinogen...

20060222639 - Wound treatment utilizing collagenase and a phosphotidylcholine organogel: The effect of the action of collagenase in treating lesions containing collagen or mixed fibrin clots (e.g., burns or ulcers) is improved by applying collagenase to the wound in combination with an organogel and a phosphotidylcholine, of which lecithin is a readily available source, particularly when the collagenase is first...

20060222642 - Compositions for the treatment of mycobacterial infections: The invention relates to the field of immunology and, more specifically, to the treatment of infectious diseases caused by mycobacteria, whereby antibody compositions are administered mucosally and in other ways for the prophylactic and therapeutic treatment of said diseases. The invention relates to the preparation of compositions of human antibodies...

20060222643 - Anti-mpl antibody: Anti-human Mpl antibodies were isolated and purified, and then anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were purified using genetic engineering techniques. Furthermore, the present inventors succeeded in humanizing anti-human Mpl sc(Fv)2. The diabodies and sc(Fv)2 were assayed for TPO-like agonistic activity, and were found to have activities higher than...

20060222644 - Humanized anti-lymphotoxin beta receptor antibodies: This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-β-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use of the antibodies alone or in combination with chemotherapeutic agent(s) in therapeutic methods....

20060222646 - Anti-tnfalpha antibodies in therapy of asthma: The present invention provides for uses of an anti-TNFα antibody or an antigen-binding fragment thereof for the manufacture of a medicament for use in the treatment of asthma or airway inflammation in an individual in need thereof. The present invention also provides for use of an anti-TNFα antibody or an...

20060222645 - Monoclonal antibodies against angptl4: Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided....

20060222648 - Kim-1 antagonists and use to modulate immune system: The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of...

20060222647 - Methods and compositions for modulating the activity of pde5: The present invention provides agents such as agonists, antibodies, antagonists or inhibitors to modulate the activity of PDE5 proteins. These compositions and methods are useful for the diagnosis or treatment of conditions associated with the presence, the deficiency, altered levels, or altered activity of PDE5 proteins....

20060222649 - Methods for inducing antigen-specific t cell tolerance: Methods for inducing antigen-specific T cell tolerance are disclosed. The methods involve contacting a T cell with: 1) a cell which presents antigen to the T cell, wherein a ligand on the cell interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function;...

20060222650 - Broad spectrum pyrogenic antagonists and vaccines directed against pyrogenic exotoxins: The invention relates to peptides comprising an amino acid sequence homologous to the amino sequence of a fragment of a pyrogenic exotoxin, and functional derivatives of said peptides, capable of eliciting protective immunity against toxic shock induced by a pyrogenic exotoxin or by a mixture of pyrogenic exotoxins. Preferred peptides...

20060222651 - Staphylococcal immunotherapeutics via donor selection and donor stimulation: A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or...

20060222652 - Molecular antigen array: The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention...

20060222653 - Antibodies operably linked to selected chemoattractants: An antibody or fragment thereof operably linked to a one or more chemoattractants selected from the group consisting of: C5a or fragments thereof; C3a or fragments thereof; C4a or fragments thereof; and, formyl-Met-Leu-Phe (fMLP)....

20060222655 - Compositions and methods for preventing and treating endotoxin-related diseases and conditions: The invention provides pharmaceutical compositions for preventing and treating endotoxin-related diseases and conditions, as well as methods for making and using such compositions....

20060222654 - Methods and compounds for raising antibodies and for screening antibody repertoires: The present invention relates to compositions and methods for raising antibodies generally comprising 1) providing highly immunogenic vesicles bearing at least one target antigen and 2) immunizing animals with the said antigen-bearing vesicles to induce antigen-specific antibody responses. The invention also relates to methods of screening antibody repertoires comprising 1)...

20060222656 - Mage-a3/hpv 16 peptide vaccines for head and neck cancer: The present invention relates to Trojan antigens, and immunogenic compositions comprising the Trojan antigens. The present invention also relates to methods of generating an immune response in a subject using the Trojan antigens or immunogenic compositions. The present invention further relates to methods of treating squamous cell carcinoma of the...

20060222659 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a...

20060222657 - Polypeptide transduction and fusogenic peptides: Due to the barrier imposed by the cell membrane, delivery of macromolecules in excess of 500 Daltons directly into cells remains problematic. However, proteins, which have been evolutionarily selected to perform specific functions, are therefore an attractive therapeutic agent to treat a variety of human diseases. In practice, the direct...

20060222658 - Vaccinia virus nucleic acids, polypeptides and immunogenic compositions: The present invention provides transcriptionally active vaccinia virus polynucleotides, recombinant vaccinia virus polypeptides, and immunogenic vaccinia virus antigens. Immunogenic compositions are also provided that may be useful as recombinant, subunit and DNA vaccines....

20060222660 - Use of dna vaccine in combination with a conventional vaccine to overcome immunogen interference: A method, composition and kit for reducing or preventing immunogenic interference in a multi-valent vaccine utilizes a nucleic acid or DNA component along with other non-nucleic acid immunogenic components....

20060222663 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors; methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus,...

20060222662 - Composition to be administered to a living being and method for marking agents: The invention relates to compositions to be administered to a living being, a method for marking agents that are administered to living beings, the use thereof, and an accelerated test....

20060222661 - Infectious hepacivirus pseudo-particles containing functional e1, e2 envelope proteins: The invention relates to the generation and the use of hepacivirus pseudo-particles containing native functional E1, E2 envelope glycoproteins assembled onto retroviral core particles. These particles are highly infectious and constitute a valid model of hepacivirus virion....

20060222664 - Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production: The present invention generally relates to the field of immunology and provides immunoprotective compositions and methods for preparing such compositions from transgenic plant cells. The present invention also relates to the field of protein production (e.g., the recombinant production of enzymes, toxins, cell receptors, ligands, signal transducing agents, cytokines, or...

20060222665 - Virus vaccine: The present invention relates to a pharmaceutical composition or a vaccine which comprises a mixture of viral protein molecules which are sequence variants of a single viral protein or of part of same. The invention furthermore relates inter alia to a DNA vaccine which codes for a mixture of structurally...

20060222667 - Apparatus for treating asthma using neurotoxin: Apparatus for providing intrabronchial delivery of neurotoxins to control the effects of asthma comprises a shaft having proximal and distal ends and a neurotoxin applicator assembly disposed on the distal end. The neurotoxin applicator assembly comprises a deployable needle assembly, a rotating needle assembly, and a needle-less injection assembly or...

20060222666 - Clostridial toxin derivatives and methods for treating pain: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting...

20060222669 - Stannsoporfin compositions and administration: Pharmaceutical compositions including stannsoporfin, drug products incorporating pharmaceutical compositions, methods of making pharmaceutical compositions, and methods of treating hyperbilirubinemia with drug products and compositions are disclosed....

20060222668 - Stannsoporfin compositions, drug products and methods of manufacture: Pharmaceutical compositions including stannsoporfin, drug products incorporating pharmaceutical compositions, methods of making pharmaceutical compositions, and methods of treating hyperbilirubinemia with drug products and compositions are disclosed....

20060222671 - Dermatological compositions and salts for the treatment of dermatological diseases: The invention relates to dermatological compositions of Oxaprozin or a closely related compound suitable adapted for the treatment of a dermatological disease, where at least two of the enzymes selected from protein tyrosine kinase Syk, protein tyrosine kinase ZAP-70 and phosphodiesterase IV play a role in mediating the dermatological disease....

20060222672 - Gaseous constituent supply device for vehicle: A gaseous constituent supply device supplies an air cannon projectile containing a predetermined gaseous constituent to an occupant in a compartment of a vehicle. This supply device includes a gaseous constituent supply chamber for reserving the gaseous constituent, an air compression unit for compressing an inside of the gaseous constituent...

20060222673 - Injectable phosphatidylcholine preparations: The present invention relates to viscous injectable phosphatidylcholine preparations and their use for the reduction or removal of localized adipose tissue (fat) deposits, and to intra-fat pad injection and implant methods of administering such preparations for the non-surgical removal or reduction of localized fatty deposits....

20060222670 - Nanocomposite microgel particles and uses thereof: The use of a nanocomposite microgel as a stimulus responsive particulate emulsifier, wherein the microgel particles comprise an inorganic particulate component and a cross-linked responsive polymer matrix....

20060222674 - Compositions and methods for the treatment and prevention of disease in plants: Non-toxic, naturally derived and economical compositions for treating and preventing bacterial or fungal disease in plants, especially citrus canker, wherein such compositions include various combinations of d-limonene, wax and monohydric alcohol are provided. Methods for making and using such compositions are also provided....

20060222675 - Personal care compositions with color changing indicator: The invention describes a composition for use in disinfecting a surface for personal use, such as a public restroom facility or telephone. The composition and delivery of the composition provides for the placement of a thin layer of disinfectant which includes a acid-base indicator. The acid-base indicator disappears as the...

20060222676 - Rodenticidal composition in the form of vegetable paste: The present invention relates to a rodenticidal composition in the form of fresh paste for enticing mice and rats wherein the flour used is mainly of a vegetable origin and the fatty matter incorporated essentially consists of palm oil....

20060222677 - Method of protecting sensitive molecules from a photo-polymerizing environment: In one embodiment, the present invention is a substrate system of photopolymerizable monomers and bioactive molecules admixed with the monomers and shielded from the monomers by an insoluble material that undergoes a solid-gel transition at body temperature. Upon polymerization, the monomers produce a cross-linked structure and the shielded bioactive molecules...

20060222678 - Biomcompatible implant coated with biocompatible fluor-hydroxyapatite and a coating method of the same: The present invention relates to a biocompatible implant coated with a biocompatible fluor-hydroxyapatite and a coating method of the same, and in particular to a method for coating a hydroxyapatite(HA) and a fluor-hydroxyapatite on a biocompatible implant Ti metal substrate having an excellent biocompatibility and mechanical property and a biocompatible...

20060222679 - System and method for loading a beneficial agent into a medical device: A system for delivery of a beneficial agent in the form of a viscous liquid or paste allows holes in a medical device to be loaded in a single step process. The loading of a beneficial agent in a paste form also provides the ability to deliver large and potentially...

20060222681 - Controlled degradation materials for therapeutic agent delivery: According to an aspect of the present invention, polymeric release regions are provided, which contain one or more partially biodegradable progenitor polymers and which control the release of one or more therapeutic agents disposed beneath or within the same. The progenitor polymers within the release regions are composed of a...

20060222680 - Method of preparing crosslinked collagen microspheres: The present invention is drawn to methods of preparing crosslinked collagen microspheres and microparticles, where a solution of soluble collagen in an aqueous acidic medium is combined with an emulsifying agent to form a first mixture of the soluble collagen solution and the emulsifying agent, the first mixture then is...

20060222682 - Nutraceutical moringa composition: The present invention incorporates portions from the Moringa plant into a nutraceutical beverage to provide a therapeutic effect in a person. The leaves, seeds, and fruit of the Moringa plant are used in the present invention to provide a biologically metabolized nutritional composition for health, well-being, and for treatment of...

20060222683 - Tongue cleaning apparatus: The present invention is a dissolvable candy which provides effective tongue scraping action. The candy is a soft pliable edible dissolvable candy material, such as a GUMMI-BEAR type confection, having a generally oval shape. A plurality of segments are formed with hard candy in one surface of the soft candy....

20060222685 - Methods of feeding animals: Methods and compositions for improved ruminant diets are disclosed. The invention relates to the use of metal ion/metal ion salts in ruminant feed, at levels from about 0.25 to about 1 g/kg dry matter, in any ruminant diet, for improvement of bypass protein content, as well as to influence the...

20060222684 - Palatable ductile chewable veterinary composition: The present invention is directed to palatable ductile chewable veterinary composition for oral administration. The composition is capable of killing endo-parasites and ecto-parasites and/or can be used for treating prophylactic or curative animal diseases, and it is useful for the treatment of any warm-blooded non-human animal, including herd animals, like...

20060222688 - Disposable gloves: A disposable glove for a hand of a human wearer that comprises a blend of polyisoprene and another non-latex glove material. The glove provides a fit and feel comparable to a latex glove, while maintaining cost-effectiveness....

20060222686 - Dry products comprising an applicator and a wax phase: This invention concerns products for cleansing and other applications, which products comprise an applicator such as a puff (pouf), pad, sponge, cotton ball, swab, brush, glove, mitt or bar, to which a wax phase has been applied. The invention further concerns the manufacture and use of such products....

20060222689 - Skin care compositions and methods: A composition for local application includes: vitamin C in an amount from about 1% to 45% w/w; vitamin B complex in an amount from about 1% to 5% w/w; carotene in an amount from about 0.1% to 3% w/w; and vitamin E in an amount from about 2% to 90%...

20060222687 - Topical anesthetic: A formulation and method for the preparation of topical anesthetics formulations, containing one or more anesthetics, in a delivery vehicle designed to promote penetration of the anesthetics into the skin and underlying tissue and to facilitate the speed of action and prolonged response. The stratum corneum layer of the skin...

20060222691 - Composition for the transdermal delivery of fentanyl: A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery...

20060222690 - Low-concentration capsaicin patch and methods for treating neuropathic pain: Described here are patches and methods for treating neuropathic pain. In some variations, the neuropathic pain-relieving patch comprises capsaicin or a capsaicin analog, wherein the concentration of the capsaicin or capsaicin analog is less than 1% by weight, and a penetration enhancer, wherein the patch is capable of relieving neuropathic...

20060222692 - Method and compositions for transdermal administration of antimicrobial medications: The present invention relates to methods and compositions for improved efficacy and delivery of time-dependent antimicrobial drug compositions to a patient. Transdermal dosage forms and methods for steady-state delivery of drug to produce and maintain a serum concentration of drug above the minimum inhibitory concentration or minimum microbicidal concentration are...

20060222693 - Transdermal patch bearing a decorative image: A transdermal patch is disclosed for administering a drug to a human user. The transdermal patch includes a pigment layer having an image formed therein, a layer including the drug, and an adhesive layer for adhering the transdermal patch to the skin....

20060222695 - Deoxycholic acid liposome-based dermatological topical preparation: A dermatological topical preparation such a cream, a lotion, an emulsion, a paste, an ointment and the likes including liposomes carrying lipo-dissolving substances encapsulated by the liposomes wall or incorporated with the liposomes wall components. The lipo-dissolving substance is released by the liposomes into the target adipose tissue or its...

20060222697 - Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal: The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free recombinant human insulin isophane and free Recombinant human regular insulin insulin and a mixture of recombinant human insulin isophane and Recombinant human regular insulin insulin associated with a water insoluble target molecule complex, wherein the...

20060222698 - Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal: The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free glargine insulin and glargine insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Glargine insulin is present within the complex in...

20060222696 - Novel liposome compositions: The present disclosure provides lipid-containing compositions, including targeted liposomes encapsulating drug, and pharmaceutical formulations thereof, as well as methods for the making and using the lipid-containing compositions, including the use of the targeted liposomes in the treatment of cancer and other diseases....

20060222694 - Stabilized topotecan liposomal composition and methods: A topotecan liposomal composition which can be reconstituted from a lyophilized form to an injectable liposome suspension having selected liposome sizes in the size range between 0.05 and 0.25 microns, and between about 85-100% liposome-entrapped topotecan is disclosed....

20060222701 - Compositions with hydrophilic drugs in a hydrophobic medium: In various embodiments of the present invention, a capsule is provided including a hydrophobic inner layer and at least one hydrophilic outer layer. The hydrophobic layer may include a hydrophilic component such as an active pharmaceutical ingredient (API) which may be fully encapsulated, partially encapsulated or part of an adsorption...

20060222699 - Flavored vegetarian cellulose capsule and methods for producing said capsule.: A flavored vegetable starch capsule and the method of manufacture of the flavored capsule is provided. The capsule may comprise (a) from about 95% to about 100% parts by weight of cellulose, such as hydroxymethylcellulose; (b) from about 0.5% to about 5.5% by weight of a suitable hydrogenated saccharide, such...

20060222700 - Tablet and capsule form of liquid active ingredient: A tablet includes a liquid active ingredient, such as benzonatate, and a powdered material, such as fumed silica. The powdered material has adsorbed a high proportion by weight of the liquid active ingredient while maintaining characteristics of a solid. The liquid active ingredient and the powdered material are compressed to...

20060222706 - Formulations of fenofibrate: The invention provides at least a composition for the treatment of elevated levels of triglycerides, comprising a therapeutically effective amount of fenofibrate or another fibrate drug intimately associated with menthol or a surfactant mixture, wherein the menthol can be menthol or menthol surfactant mixture, and wherein the surfactant mixture can...

20060222707 - Formulations of fenofibrate: The invention provides at least a composition for the treatment of elevated levels of triglycerides, comprising a therapeutically effective amount of a fibrate drug, preferably fenofibrate, intimately associated with a surfactant mixture, preferably a mixture comprising PGE 6000 and poloxamer 407. The invention also provides a method for the treatment...

20060222703 - Pharmaceutical composition and preparation method thereof: The invention relates to an oral solid pharmaceutical composition comprising pharmacologically effective amounts of entacapone, levodopa and carbidopa, or a pharmaceutically acceptable salt or hydrate thereof, and one or more pharmaceutically acceptable excipients, wherein the excipients are long-chain polymers having an equilibrium moisture content of at least 2%, and to...

20060222705 - Pharmaceutical tablet and apparatus and method for making: A punch and die set include a die with a single large cavity which can receive dry particles of relatively large dimensions or large arching indexes as compared to the transverse dimensions of the tablets formed by the particles, e.g., 1.5 mm diameter and 1 mm height. The upper and...

20060222704 - System and a method for labeling a substrate: A method for labeling a substrate includes positioning the substrate adjacent to an inkjet material dispenser, and selectively jetting an edible ink onto the substrate with the inkjet material dispenser. The edible ink is configured to exhibit a known fluorescent emissive profile when exposed to a visible light....

20060222702 - System and method for optically tracking objects using a spectral fingerprint of fluorescent compounds: A method for labeling a substrate includes positioning the substrate adjacent to an inkjet material dispenser, and selectively jetting an edible ink onto the substrate with the inkjet material dispenser. The edible ink is configured to exhibit a known fluorescent emissive profile when exposed to an ultraviolet light....

20060222708 - Wafer comprising steroid hormones: The invention relates to a pharmaceutical composition in the form of a system in film form for transmucosal administration of steroid hormones. An administration system for steroid hormones which dissolves in the mouth and which releases with a high bioavailability is disclosed. The administration system in film form dissolves in...

20060222709 - Metformin methods and formulations for treating chronic constipation: The present invention is directed to methods and formulations for treating chronic constipation. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of metformin for treating chronic constipation and further comprise at least one pharmaceutically acceptable ingredient to control the release of...

20060222710 - Composition of and method for preparing stable particles in a frozen aqueous matrix: The present invention discloses a composition of a stable suspension of a poorly water soluble pharmaceutical agent or cosmetic in the form of particles of the pharmaceutical agent or cosmetic suspended in a frozen aqueous matrix and method for its preparation. The composition is stable for a prolonged period of...

20060222711 - Composition of and method for preparing stable particles in a frozen aqueous matrix: The present invention discloses a composition of a stable suspension of a poorly water soluble pharmaceutical agent or cosmetic in the form of particles of the pharmaceutical agent or cosmetic suspended in a frozen aqueous matrix and method for its preparation. The composition is stable for a prolonged period of...

20060222712 - Acne gel: This combination of clindamycin (1%) and tretinoin (0.025%), solubilized in a hydrogel, resulted in significantly greater improvements in acne vulgaris (reduced lesion counts and ISGA) than either drug alone or vehicle and effectively treated both non-inflammatory and inflammatory lesions with a convenient, once-daily application....

20060222713 - Extended release pharmaceutical composition of phenytoin sodium: The present invention relates to extended release pharmaceutical composition of phenytoin sodium that includes a blend of phenytoin sodium and one or more hydrophilic polymers. The blend forms a matrix after contacting an aqueous media and the matrix retains at least about 20% of the phenytoin after 1 hour. It...

20060222714 - Agent for preventing and ameliorating constipation: A novel agent for preventing and healing constipation which heals the symptom of constipation very effectively and entails absolutely no side effect is provided. This agent for preventing and healing constipation is formed by containing a hydrogen of a polyvalent metal salt of alginic acid possessing a spherical or ovaloid...

20060222716 - Colloidal solid lipid vehicle for pharmaceutical use: The invention provides a drug carrier that includes a solid lipid nanoparticle (SLN), wherein the SLN includes tocopherol or a derivative thereof. The invention also provides a pharmaceutical composition that includes a SLN and a biologically active compound, wherein the SLN comprises tocopherol or a derivative thereof. The present invention...

20060222715 - Particles containing an acitve agent in the form of a co-precipitate: The invention relates to particles containing an active agent in the form of a co-precipitate, to a method for producing said particles and to pharmaceutical forms containing said particles....

20060222717 - Agent for preventing and curing pathologies states associated with endorphin deficiency in organism: The inventive powder is made of ossified horns of reindeer and contains 25 pmol/g of endorphins in the form of agent for preventing and treating pathological states associated with endorphin deficiency in organism....

20060222718 - Aqueous pharmaceutical solution comprising oxymetazoline and/or xylometazoline: The present invention relates to a stable aqueous solution comprising oxymetazoline and/or xylometazoline, a zinc salt and a buffer salt. The aqueous solution is particularly suitable for local administration into the nose for decongesting the mucous membrane....

20060222720 - Anorectic agent and air regulator for diet: An anorectic agent contains an aqueous solvent extract of Vernonia cinerea as an active ingredient, or preferably contains aqueous solvent extracts of Vernonia cinerea and mulberry as active ingredients. The liquid content of the anorectic agent is evaporated so that a dieter can inhale its vapor. The active ingredients are...

20060222719 - Articles of manufacture made from agave residue, and methods for making such articles: Articles of manufacture are produced from a composition comprising agave plant residue and a thermosetting polymer resin....

20060222721 - Composition for treatment of menopause: A novel herbal extract, MF101, is effective in the treatment of symptoms of menopause....

20060222722 - Sublingual methods of treatment to alleviate or prevent arthritis: Methods of treating arthritis and associated symptoms are provided by administering a composition comprising feverfew extract and ginger extract sublingually to a patient in need thereof. Treatments are surprisingly effective with low total administered amounts of feverfew extract and ginger extract....

20060222724 - Reproductive cell system: Compositions or extracts (2)(15)(24)(25)(16)(23)(31)(36)(41) obtained from the fruit (4) or leaves (26) of plants of the genus Hippophea (1) and methods of using such compositions or extracts to reduce loss of reproductive cell function....

20060222723 - Terpene-based composition of substances, a method for its preparation and a method for its dispersal into the atmosphere: A composition of terpene-based substances comprises a sesquiterpene fraction and/or a triterpene fraction derived from natural resins in which the fractions are intimately mixed with a gum component. The sesquiterpene and/or the triterpene fraction is present in the composition, separated from the gum component....

20060222725 - Extracts of passion fruit and uses thereof: An extract of passion fruit is prepared. The extract has the effect of lowering blood pressure and serum nitric oxide levels in mammals. The extract also provides a hepatoprotective effect, as well as antioxidant and anti-inflammatory effects in mammals. A novel compound was identified in the extract and given the...